<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11005036</article-id>
    <article-id pub-id-type="pmid">38289046</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01517</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SerotoninAI: Serotonergic
System Focused, Artificial
Intelligence-Based Application for Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6660-4446</contrib-id>
        <name>
          <surname>Łapińska</surname>
          <given-names>Natalia</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2801-6197</contrib-id>
        <name>
          <surname>Pacławski</surname>
          <given-names>Adam</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1537-9650</contrib-id>
        <name>
          <surname>Szlęk</surname>
          <given-names>Jakub</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4394-9115</contrib-id>
        <name>
          <surname>Mendyk</surname>
          <given-names>Aleksander</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Pharmaceutical Technology and Biopharmaceutics, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
      <aff id="aff2"><label>‡</label>Doctoral
School of Medicinal and Health Sciences, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.szlek@uj.edu.pl</email>. Tel.: <phone>+48-(12)-6205604</phone>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>7</issue>
    <issue-title>Machine
Learning in Bio-cheminformatics</issue-title>
    <fpage>2150</fpage>
    <lpage>2157</lpage>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>09</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>01</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>01</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0004" id="ab-tgr1"/>
      </p>
      <p>SerotoninAI is an innovative web application for scientific
purposes
focused on the serotonergic system. By leveraging SerotoninAI, researchers
can assess the affinity (pKi value) of a molecule to all main serotonin
receptors and serotonin transporters based on molecule structure introduced
as SMILES. Additionally, the application provides essential insights
into critical attributes of potential drugs such as blood–brain
barrier penetration and human intestinal absorption. The complexity
of the serotonergic system demands advanced tools for accurate predictions,
which is a fundamental requirement in drug development. SerotoninAI
addresses this need by providing an intuitive user interface that
generates predictions of pKi values for the main serotonergic targets.
The application is freely available on the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://serotoninai.streamlit.app/">https://serotoninai.streamlit.app/</uri>, implemented in Streamlit with all major web browsers supported.
Currently, to the best of our knowledge, there is no tool that allows
users to access affinity predictions for serotonergic targets without
registration or financial obligations. SerotoninAI significantly increases
the scope of drug development activities worldwide. The source code
of the application is available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Uniwersytet Jagiellonski Collegium Medicum</institution>
            <institution-id institution-id-type="doi">10.13039/100009045</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>7N42/DBS/000205</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>The rise and development
of artificial intelligence (AI) tools
have a revolutionary impact on many areas of science and industry.
In the field of drug design, AI is showing the potential to change
traditional approaches, enabling faster and more efficient discovery
and development of new therapeutic agents.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> One
of the benefits of AI is the development of advanced QSAR (quantitative
structure–activity relationship) and QSPR (quantitative structure–property
relationship) models. Their ability to screen new active compounds,
possible side effects, bioavailability and other properties can speed
up and increase cost effectiveness both of the drug discovery and
development phases.<sup><xref ref-type="bibr" rid="ref3">3</xref>−<xref ref-type="bibr" rid="ref6">6</xref></sup></p>
    <p>Our work focuses on serotonin receptors and transporters.
Selected
biological targets are important for many drugs that impact the central
nervous system (CNS). Substances that affect the serotonergic system
are used to treat mood, migraine, regulate sleep, and treat neurotic
disorders or eating disorders. Furthermore, recent studies show that
they can improve cognitive function. Preliminary studies also show
that they may represent an even broader spectrum of therapeutic applications
than CNS activity. For example, the serotonin 5-HT2C receptor has
a role in impulse control, and the 5-HT3 receptor plays a role in
controlling nausea and vomiting.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref></sup></p>
    <p>SerotoninAI is an application
focused on compounds with a serotonergic
activity. It allows predictions of affinity for various 5-HT receptors
as well as the serotonin transporter. The affinity for a selected
biological target ensures a potential application of a molecule as
a future drug and allows us to anticipate possible side effects. Moreover,
SerotoninAI predicts human intestinal absorption (HIA) and blood–brain
barrier (BBB) penetration of the given chemical structure. For the
molecule, a confirmed BBB penetration is a crucial property for drugs
acting on the central nervous system, whereas extensive HIA ensures
feasibility of the oral administration route, the most preferred and
acceptable one in the therapy. The artificial intelligence (AI)-based
system for HIA has been developed on data sets with serotonergic ligands,
which limits its application to these molecules only.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></p>
    <p>There are a number of ready-to-use programs for assessing
protein–molecule
interactions which the main task is to dock molecules in the corresponding
protein, such as NovaDock<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and AutoDock.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> On the other hand, VEGA QSAR<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and QSAR TOOLBOX<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> do not provide
predictions of affinity for selected receptors. Their application
focuses on physical and chemical properties and also ADME-TOX properties.
In contrast, typical QSAR models are provided by applications such
as QSAR-Co<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and PharmQSAR.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> In the case of QSAR-Co, the prediction capabilities
are limited to classification models. Moreover, to obtain predictions,
the user needs to download and run the tool’s own machine,
which might introduce some difficulties related to OS/machine specification.
Moreover, the authors of the application do not provide ready-to-use
models related to the serotonin system. PharmQSAR allows the creation
of statistical models using techniques CoMFA (Comparative Molecular
Field Analysis) and CoMSIA (Comparative Molecular Similarity Indices
Analysis)<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> and also does not provide models
for serotonin receptors and transporters. In the aforementioned applications
for QSAR models, whether ready-made or with the ability to create
them, registration is required, which greatly limits the use of such
an application. Provided preliminary limitations for users prevent
us from directly comparing the presented systems with our models.</p>
    <p>The only tool available without registration that provides QSAR
models is aiQSAR.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> In order to use the
ready-made models, we need to download the applications to our own
machine. However, among the 38 biological targets, there is none related
to the serotonin system. A publication describing QSAR models for
serotonin receptors is the work of Kausar et al.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> They describe the results for most serotonin receptors,
but we have no way of comparing the results because databases are
not available (no information about training and test set beyond the
number of molecules). When considering the available tools, we decided
to create SerotoninAI as the missing piece to accelerate the drug
discovery process.</p>
    <p>SerotoninAI as a web-based app allows users
to easily obtain predictions
for chosen molecules without the need for installing any tools on
their own computers, as well as without any programming skills. To
the best of our knowledge, SerotoninAI is the first affinity prediction
tool for serotonin targets without mandatory registration of a user.
Moreover, the only information needed from the user side is SMILES
(Simplified Molecular Input Line Entry Specification) of a molecule.
It is worth mentioning that the application is distributed under the
GNU General Public License version 3<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> and
the source code is provided on the GitHub platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>).</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Results and Discussion</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Databases</title>
      <p>The application uses QSAR
models developed on data extracted from two leading databases, namely,
ZINC and ChEMBL (data extracted in December 2022).<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> Data were acquired for each target involving serotonergic activity,
that is, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4,
5-HT5A, 5-HT6, 5-HT7, and the serotonin transporter SERT. Despite
the presence of ligands for 5-HT1E and 5-HT1F as well as 5-HT5B receptors
these databases were not used to create models due to their small
size (&lt;500 molecules) resulting in the limited applicability domain.
Our approach was to provide models based only on the experimentally
validated data; therefore, no decoys were used in any of the training
or testing data sets.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>
      <p>The dependent
variable was the value of ligand affinity presented as the negative
logarithm of the inhibition constant, the pKi value. In the data preparation
part, duplicates were first removed from the ZINC and ChEMBL databases
separately, and invalid SMILES were removed. No other specific structure
curation was employed. The two databases were then merged, and some
molecules were present in both databases. Molecule pairs with a pKi
difference greater than 0.1 were removed from the database. In the
group of molecule pairs with a pKi difference equal to or less than
0.1, the ZINC molecule was selected as the reference substance. The
databases were randomly divided into training and test sets at a ratio
of 80:20. The former part of the data (80%) was used to develop QSAR
models according to the 10-fold cross validation scheme, and the latter
(20%) was used as an external test set. <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> shows histograms of pKi values for each
biological target according to the training and test set.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Histograms
of the pKi values: (A) 5-HT1A serotonin receptor. (B)
5-HT1B serotonin receptor. (C) 5-HT1D serotonin receptor. (D) 5-HT2A
serotonin receptor. (E) 5-HT2B serotonin receptor. (F) 5-HT2C serotonin
receptor. (G) 5-HT3 serotonin receptor. (H) 5-HT4 serotonin receptor.
(I) 5-HT5A serotonin receptor. (J) 5-HT6 serotonin receptor. (K) 5-HT7
serotonin receptor. (L) Serotonin transporter SERT.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0001" id="gr1" position="float"/>
      </fig>
      <p>The database for predicting HIA was described in
our previous work;<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> the source of the
data was literature data and
the ChEMBL database.</p>
      <p>QSPR classification model of BBB permeability
was based on the
database collected from the work of Miao et al.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> (data set 1 and data set 2) and enriched by us with data
from OCHEM database<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> (data extracted in
July 2023). It resulted in 2853 molecules in the training set. An
independent test set from the article by Miao et al. remained in the
test set of our experiment (161 molecules) in order to better compare
our developed QSPR model.</p>
      <p>All data are available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">Supporting Information</ext-link> as a single database.zip
file containing separate training/test
csv files for each respective biological target.</p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Molecular Representation</title>
      <p>Mordred
descriptors were used as a molecular representation of chemical structures.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Mordred effectiveness in this field and suitability
for interpretation has been tested in our previous work.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> QSAR and QSPR models were created based on two-dimensional
descriptors to prevent the risk of variability in three-dimensional
descriptors due to nonconvergent molecules’ optimization. Based
on SMILES, SerotoninAI automatically creates the molecular descriptors
required by the models.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>QSAR and QSPR Models</title>
      <p>Modeling was
performed with the mljar-supervised tool, which belongs to the field
of Automated Machine Learning (AutoML).<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> In the case of receptors, serotonin transporter and BBB permeability
models were de novo created for the purpose of the presented application.
On the other hand, for human intestinal absorption, the AI-based system
has already been published<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and has been
implemented in this application without any further modifications.</p>
      <p>QSAR regression models were created according to the 10-fold cross-validation
scheme (10-CV) on 80% of the curated databases. For each target, about
2000 models were developed. We used root-mean-square error (RMSE)
and coefficient of determination (<italic>R</italic><sup>2</sup>)
values to evaluate and select the best models (<xref rid="eq1" ref-type="disp-formula">eqs <xref rid="eq1" ref-type="disp-formula">1</xref></xref> and <xref rid="eq2" ref-type="disp-formula">2</xref>), in accordance
with the guidelines of the Organization for Economic Co-operation
and Development’s QSAR models.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The results were analyzed for the training set (10-CV) and the separate
test set (20%). In <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, we show the detailed results for each QSAR model.<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m001" position="anchor"/><label>1</label></disp-formula>where RMSE = root-mean-square
error, obs<sub><italic>i</italic></sub> and pred<sub><italic>i</italic></sub> = observed and predicted values, <italic>i</italic> = data
record number, and <italic>n</italic> = total number of records.<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m002" position="anchor"/><label>2</label></disp-formula>where <italic>R</italic><sup>2</sup> = the coefficient of determination, SS<sub>res</sub> = the
sum of squares of the residual errors, S<italic>S</italic><sub>tot</sub> = the total sum of the errors, obs<sub><italic>i</italic></sub> and
pred<sub><italic>i</italic></sub> = observed and predicted values,
and obs = arithmetical mean of observed values.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Number of Ligands for Each Target,
Number of Descriptors Used for QSAR Models after Removing Constant
and Highly Correlated Variables, Results for Training Set and Test
Set, and Type of Each Model of QSAR Models</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Number of ligands</th>
              <th style="border:none;" align="center">Number of descriptors</th>
              <th style="border:none;" align="center">RMSE 10-CV</th>
              <th style="border:none;" align="center">R<sup>2</sup> 10-CV</th>
              <th style="border:none;" align="center">RMSE test</th>
              <th style="border:none;" align="center">R<sup>2</sup> test</th>
              <th style="border:none;" align="center">Model type</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">10,175</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.555</td>
              <td style="border:none;" align="center">0.733</td>
              <td style="border:none;" align="center">0.629</td>
              <td style="border:none;" align="center">0.660</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">1833</td>
              <td style="border:none;" align="center">710</td>
              <td style="border:none;" align="center">0.627</td>
              <td style="border:none;" align="center">0.731</td>
              <td style="border:none;" align="center">0.558</td>
              <td style="border:none;" align="center">0.805</td>
              <td style="border:none;" align="center">Ensemble model (5x Xgboost, 4x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">2072</td>
              <td style="border:none;" align="center">739</td>
              <td style="border:none;" align="center">0.566</td>
              <td style="border:none;" align="center">0.836</td>
              <td style="border:none;" align="center">0.536</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">Ensemble model (5x
Xgboost, 4x LightGBM, 2x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6926</td>
              <td style="border:none;" align="center">703</td>
              <td style="border:none;" align="center">0.582</td>
              <td style="border:none;" align="center">0.769</td>
              <td style="border:none;" align="center">0.567</td>
              <td style="border:none;" align="center">0.764</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">2821</td>
              <td style="border:none;" align="center">723</td>
              <td style="border:none;" align="center">0.561</td>
              <td style="border:none;" align="center">0.674</td>
              <td style="border:none;" align="center">0.607</td>
              <td style="border:none;" align="center">0.608</td>
              <td style="border:none;" align="center">Ensemble model (6x Xgboost, 2x LightGBM, 5x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">5097</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">0.625</td>
              <td style="border:none;" align="center">0.673</td>
              <td style="border:none;" align="center">0.603</td>
              <td style="border:none;" align="center">0.685</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">562</td>
              <td style="border:none;" align="center">665</td>
              <td style="border:none;" align="center">0.837</td>
              <td style="border:none;" align="center">0.672</td>
              <td style="border:none;" align="center">0.867</td>
              <td style="border:none;" align="center">0.680</td>
              <td style="border:none;" align="center">Ensemble model (2x Xgboost, 3x CatBoost, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT4</td>
              <td style="border:none;" align="center">949</td>
              <td style="border:none;" align="center">516</td>
              <td style="border:none;" align="center">0.682</td>
              <td style="border:none;" align="center">0.753</td>
              <td style="border:none;" align="center">0.690</td>
              <td style="border:none;" align="center">0.697</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.575</td>
              <td style="border:none;" align="center">0.797</td>
              <td style="border:none;" align="center">0.568</td>
              <td style="border:none;" align="center">0.761</td>
              <td style="border:none;" align="center">Ensemble model (3x Xgboost, 3x CatBoost,
1x ExtraTrees, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">5925</td>
              <td style="border:none;" align="center">688</td>
              <td style="border:none;" align="center">0.579</td>
              <td style="border:none;" align="center">0.777</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.749</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">4411</td>
              <td style="border:none;" align="center">727</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.684</td>
              <td style="border:none;" align="center">0.601</td>
              <td style="border:none;" align="center">0.728</td>
              <td style="border:none;" align="center">CatBoost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8091</td>
              <td style="border:none;" align="center">541</td>
              <td style="border:none;" align="center">0.490</td>
              <td style="border:none;" align="center">0.851</td>
              <td style="border:none;" align="center">0.492</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>, we have
presented examples of drugs available on the market along with their
affinities from literature sources and pKi values predicted by the
SerotoninAI.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>SerotoninAI’s Predictions and
Literature Values of pKi for Drug Examples Related to Serotonergic
System</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Drug</th>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Experimental/Literature pKi value</th>
              <th style="border:none;" align="center">SerotoninAI
prediction</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Fluoxetine<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></td>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6.150</td>
              <td style="border:none;" align="center">6.631</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.371</td>
              <td style="border:none;" align="center">6.308</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8.708</td>
              <td style="border:none;" align="center">8.013</td>
            </tr>
            <tr>
              <td rowspan="11" style="border:none;" align="center">Aripiprazole<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">8.252</td>
              <td style="border:none;" align="center">7.527</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">6.081</td>
              <td style="border:none;" align="center">5.913</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">7.167</td>
              <td style="border:none;" align="center">6.753</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">8.060</td>
              <td style="border:none;" align="center">8.366</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">9.444</td>
              <td style="border:none;" align="center">7.982</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.119</td>
              <td style="border:none;" align="center">7.195</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">6.202</td>
              <td style="border:none;" align="center">6.160</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">5.907</td>
              <td style="border:none;" align="center">5.890</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">6.244</td>
              <td style="border:none;" align="center">6.716</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">7.987</td>
              <td style="border:none;" align="center">7.570</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">5.967</td>
              <td style="border:none;" align="center">6.646</td>
            </tr>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Zolmitriptan<sup><xref ref-type="bibr" rid="ref31">31</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">7.105</td>
              <td style="border:none;" align="center">6.562</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">8.377</td>
              <td style="border:none;" align="center">8.089</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">9.199</td>
              <td style="border:none;" align="center">8.733</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Clozapine<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">6.990</td>
              <td style="border:none;" align="center">6.357</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The examples presented above are also included in
curated databases
prepared to create QSAR models, which do not constitute the usefulness
of such a model for unseen examples of molecules. Therefore, we decided
to test the created models on the latest available data. For this
purpose, we reviewed the literature from 2022, when the first databases
were created. New experimental data were available for seven biological
targets (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and
5-HT7).<sup><xref ref-type="bibr" rid="ref33">33</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> In <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>, we present
summary results for each receptor and the sum of predictions, using
SerotoninAI, located in four categories: when the prediction difference
was less than 0.5, greater than or equal to 0.5 and less than 1.0,
the third group being prediction differences equal to or greater than
1.0 and less than 2.0, and the last group indicating a very large
prediction difference, a value equal to or greater than 2.0. All predictions
are available in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">Supporting Information S1</ext-link>. The worst predictions are seen for the 5-HT5A receptor. In our
opinion, this is due to too little differentiated data. Of the seven
targets for which external data were available, the database for the
5-HT5A receptor was the smallest (720 molecules).</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Summary of pKi Pedictions by SerotoninAI
for New Experimental Data Available in the Literature in the Years
2022–2023</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th colspan="4" align="center">Differences
of literature data and SerotoninAI predictions of pKi<hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">receptor</th>
              <th style="border:none;" align="center">&lt;0.5</th>
              <th style="border:none;" align="center">≥0.5 and &lt;1.0</th>
              <th style="border:none;" align="center">≥1.0 and &lt;2.0</th>
              <th style="border:none;" align="center">≥2.0</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">2</td>
              <td style="border:none;" align="center">13</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">31</td>
              <td style="border:none;" align="center">15</td>
              <td style="border:none;" align="center">6</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">3</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">4</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">24</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">8</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">23</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">total</td>
              <td style="border:none;" align="center">102</td>
              <td style="border:none;" align="center">44</td>
              <td style="border:none;" align="center">38</td>
              <td style="border:none;" align="center">8</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The QSPR model for BBB penetration was a binary classification
model (1, molecule penetrates to brain; 0, no penetration). It was
also created according to 10-CV. To evaluate the model, classification
metrics like accuracy, precision, recall, F1 score, and Matthews correlation
coefficient (MCC) were used (<xref rid="eq3" ref-type="disp-formula">eqs <xref rid="eq3" ref-type="disp-formula">3</xref></xref>–<xref rid="eq7" ref-type="disp-formula">7</xref>). These results and confusion
matrices for the training and test set are shown in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> and <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>. We compared our results on the test set
with the recent article on BBB penetration,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and our model resulted in more accurate predictions. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">Supporting Information S2</ext-link> provides a detailed
description of these results.<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m004" position="anchor"/><label>4</label></disp-formula><disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m005" position="anchor"/><label>5</label></disp-formula><disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m006" position="anchor"/><label>6</label></disp-formula>where TP = true positive, TN = true negative,
FP = false positive, and FN = false negative.<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m007" position="anchor"/><label>7</label></disp-formula></p>
      <table-wrap id="tbl4" position="float">
        <label>Table 4</label>
        <caption>
          <title>Summary of Classification Metrics
for Training and Test Set for the Blood–Brain Barrier Penetration
Model</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center">Training set (10-CV)</th>
              <th style="border:none;" align="center">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">Accuracy</td>
              <td style="border:none;" align="center">0.94</td>
              <td style="border:none;" align="center">0.87</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Precision</td>
              <td style="border:none;" align="center">1.00</td>
              <td style="border:none;" align="center">0.80</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Recall</td>
              <td style="border:none;" align="center">0.91</td>
              <td style="border:none;" align="center">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">F1 score</td>
              <td style="border:none;" align="center">0.96</td>
              <td style="border:none;" align="center">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Matthews correlation coefficient</td>
              <td style="border:none;" align="center">0.88</td>
              <td style="border:none;" align="center">0.76</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Number
of compounds</td>
              <td style="border:none;" align="center">2853</td>
              <td style="border:none;" align="center">161</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Type of model</td>
              <td colspan="2" align="center">Ensemble model (5x Xgboost, 7x NeuralNetwork, 2x LightGBM)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Confusion matrices for training and test sets: blood–-brain
barrier QSPR model.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0002" id="gr2" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Applicability Domain</title>
      <p>The major challenge
that researchers face in developing QSAR or QSPR models is the scarcity
of data. Based on the available data, the model predicts correctly
within the relevant ranges of descriptors. For these reasons, SerotoninAI
with each prediction provides information on whether the studied compound
is within the applicability domain (AD) or not. Naturally, within-AD
predictions are characterized with higher accuracy even though the
compound is unknown to the system, namely, beyond the training data.</p>
      <p>The AD was obtained based on the 10 most important descriptors
for each model. The importance ranking of the descriptors was obtained
using SHAP analysis. SHAP (Shapley Additive Explanations) is a method
used to explain complex AI/ML models. It is based on a concept called
the Shapley value, introduced by Lloyd Shapley in 1952.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Shapley, who was distinguished for his input
in game theory by the Nobel Memorial Prize in Economic Sciences in
2012, focused on how to fairly divide rewards from the game among
cooperating players. The solution for the analyzed problem should
allow for splitting the reward of the team among all players in a
proportional way to its contribution to the result and at the same
time fulfill criteria of efficiency, additivity, symmetry, and null
player presence detection. The unique solution for that problem is
the Shapley value which divides the reward based on each player’s
marginal contribution, ensuring fairness. In the realm of predictive
modeling, this framework can be adapted to assess the incremental
contribution of each input variable of the model to the predicted
outcome.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> In this study, we employed SHAP
analysis to examine the overarching influence of each variable, considering
both the magnitude and the direction (high or low values of the variable)
of its impact on the final prediction. This analysis was conducted
in Python environment, leveraging a framework developed by Szlęk,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> further augmented with a wrapper for the mljar
package. Summary plots of SHAP analysis for each obtained model are
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">Supporting Information S3</ext-link>,
except for the HIA model, where the entire analysis was described
in previous article.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The values of these
descriptors in the training set were transformed via Min–Max
normalization. A compound is under AD if seven descriptors are in
the range between minimum and maximum values of the training set. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> presents examples
of compounds within and outside the applicability domain.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>A comparison
of the molecule’s applicability domains. (Left)
A molecule within the applicability domain. (Right) A molecule out
of the applicability domain. The gray area indicates the application
domain.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0003" id="gr3" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.5">
      <label>2.5</label>
      <title>Application Development</title>
      <p>SerotoninAI
was developed using Streamlit, an open-source Python library that
simplifies the process of developing web applications. It enables
developers to create interactive and user-friendly web applications
using Python scripts.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Our app includes
pharmacological descriptions for each biological target and a medical
and biopharmaceutical introduction to intestinal permeability and
blood–brain barrier based on literature data.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> This enables scientists to better
understand the mechanisms of action of these receptors and identify
potential targets for new drugs. This knowledge can accelerate the
drug discovery process, enabling scientists to design compounds with
the desired pharmacological properties. The graphics page was enhanced
with images created using Canva software.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Implementation</title>
    <p>SerotoninAI operates
in several modes. The user can obtain predictions
for the target’s affinity or class of HIA and BBB, either for
a single compound or based on a collection of molecules represented
by a CSV file, the so-called batch mode. However, due to limited resources
provided by the Streamlit server, we encourage users to run batch
mode locally on their own machines. From the user’s perspective,
the model makes predictions based on SMILES, imported directly from
the DrugBank/ChEMBL/ZINC without a specific structure curation. In
the case of a CSV file, compounds should be represented in a column
named “smiles”. There is also the possibility to draw
molecules and obtain particular SMILES.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup></p>
    <p>Another feature of the application is to obtain a prediction
for
one biological target only, multiple user-selected targets, or all
of them at once. Depending on the research needs, scientists may choose
which serotonin receptors are relevant. This mode works with only
a CSV file. It is worth remembering that with more molecules and more
targets under study, the prediction time increases. The result of
the predictions for multiple molecules is a downloadable file with
ready-made predictions. As in the case of individual predictions for
a single target, information about the applicability domain appears.
In the case of batch mode, it takes the values “True”
or “False”, where “True” means that the
tested compound is in the AD defined in <xref rid="sec2.4" ref-type="other">section <xref rid="sec2.4" ref-type="other">2.4</xref></xref>.</p>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusion</title>
    <p>The developed SerotoninAI
application is publicly available AI-based
software for obtaining affinity and permeability predictions for the
intestinal wall and blood–brain barrier. The use of such predictions
for serotonin receptors and transporters can significantly accelerate
the time to find new compounds with potential pharmacological activity,
mainly in the field of central nervous system diseases. This application,
governed by the GNU General Public License version 3,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> comes with no liability from the authors for the obtained
results. The published version of the app is not password protected;
neither is the data privacy ensured. For the latter, the user must
download the source code and install the app in the controlled environment.</p>
    <p>Limitations due to the small amount of data to create models for
several serotonin receptors (5-HT1E, 5-HT1E, and 5-HT5B) will be overcome
when more data about ligands for these receptors are published. SerotoninAI
will be updated on an ongoing basis for at least 2 years when larger
databases become available and/or better predictive models can be
obtained. Due to limited resources available to streamlit applications,
batch mode computations should be run locally.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The data underlying
this study are available in the published article and its <xref rid="notes-1" ref-type="notes">Supporting Information</xref>, except the data used
for developing HIA model, which are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/HIA_5-HT">https://github.com/nczub/HIA_5-HT</uri>.</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supporting Information S1, Table 1: prediction results
of external data of ligands for seven targets of serotonin system
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S2, Table 2: prediction results
of 161 compounds, test set of blood–brain barrier model (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S3, Figure: Summary plot of SHAP
analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">PDF</ext-link>)</p></list-item><list-item><p>Databases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">ZIP</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_001.xlsx">
        <caption>
          <p>ci3c01517_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_002.xlsx">
        <caption>
          <p>ci3c01517_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_003.pdf">
        <caption>
          <p>ci3c01517_si_003.pdf</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile4">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_004.zip">
        <caption>
          <p>ci3c01517_si_004.zip</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e1139-autogenerated">
    <p>The authors declare
no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This research/study was carried out with
the use of research
infrastructure cofinanced by the Smart Growth Operational Programme
POIR 4.2 project no. POIR.04.02.00-00-D023/20. Research was partially
supported by Jagiellonian University Medical College in Kraków,
Grant Number 7N42/DBS/000205. Equipment was also cofinanced by the
qLIFE Priority Research Area under the program “Excellence
Initiative—Research University” at Jagiellonian University.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>10-CV</term>
        <def>
          <p>10-fold
cross-validation</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT</term>
        <def>
          <p>5-hydroxytryptamine,
serotonin</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1A</sub></term>
        <def>
          <p>serotonin 1A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1B</sub></term>
        <def>
          <p>serotonin 1B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1D</sub></term>
        <def>
          <p>serotonin
1D receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1E</sub></term>
        <def>
          <p>serotonin 1E receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1F</sub></term>
        <def>
          <p>serotonin 1F receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2A</sub></term>
        <def>
          <p>serotonin
2A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2B</sub></term>
        <def>
          <p>serotonin 2B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2C</sub></term>
        <def>
          <p>serotonin 2C receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>3</sub></term>
        <def>
          <p>serotonin
3 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>4</sub></term>
        <def>
          <p>serotonin 4 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5A</sub></term>
        <def>
          <p>serotonin 5A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5B</sub></term>
        <def>
          <p>serotonin 5B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>6</sub></term>
        <def>
          <p>serotonin
6 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>7</sub></term>
        <def>
          <p>serotonin 7 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>AD</term>
        <def>
          <p>Applicability domain</p>
        </def>
      </def-item>
      <def-item>
        <term>AI</term>
        <def>
          <p>Artificial Intelligence</p>
        </def>
      </def-item>
      <def-item>
        <term>AutoML</term>
        <def>
          <p>Automated Machine Learning</p>
        </def>
      </def-item>
      <def-item>
        <term>BBB</term>
        <def>
          <p>blood–brain barrier</p>
        </def>
      </def-item>
      <def-item>
        <term>CNS</term>
        <def>
          <p>central nervous system</p>
        </def>
      </def-item>
      <def-item>
        <term>HIA</term>
        <def>
          <p>human intestinal
absorption</p>
        </def>
      </def-item>
      <def-item>
        <term>MCC</term>
        <def>
          <p>Matthews
correlation coefficient</p>
        </def>
      </def-item>
      <def-item>
        <term>QSAR</term>
        <def>
          <p>quantitative structure–activity relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>QSPR</term>
        <def>
          <p>quantitative structure–property
relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>R<sup>2</sup></term>
        <def>
          <p>coefficient of determination</p>
        </def>
      </def-item>
      <def-item>
        <term>RMSE</term>
        <def>
          <p>root-mean-square error</p>
        </def>
      </def-item>
      <def-item>
        <term>SHAP</term>
        <def>
          <p>SHapley Additive exPlanations</p>
        </def>
      </def-item>
      <def-item>
        <term>SMILES</term>
        <def>
          <p>simplified molecular-input
line-entry system</p>
        </def>
      </def-item>
      <def-item>
        <term>TN</term>
        <def>
          <p>true negative</p>
        </def>
      </def-item>
      <def-item>
        <term>TP</term>
        <def>
          <p>true positive;</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence in drug discovery and development</article-title>. <source>Drug Discovery Today.</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Gupta</surname><given-names>R.</given-names></name>; <name><surname>Srivastava</surname><given-names>D.</given-names></name>; <name><surname>Sahu</surname><given-names>M.</given-names></name>; <name><surname>Tiwari</surname><given-names>S.</given-names></name>; <name><surname>Ambasta</surname><given-names>R. K.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name><article-title>Artificial intelligence to deep learning:
Machine intelligence approach
for drug discovery</article-title>. <source>Mol. Divers.</source><year>2021</year>, <volume>25</volume>, <fpage>1315</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1007/s11030-021-10217-3</pub-id>.<pub-id pub-id-type="pmid">33844136</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Kwon</surname><given-names>S.</given-names></name>; <name><surname>Bae</surname><given-names>H.</given-names></name>; <name><surname>Jo</surname><given-names>J.</given-names></name>; <name><surname>Yoon</surname><given-names>S.</given-names></name><article-title>Comprehensive ensemble in QSAR prediction
for drug discovery</article-title>. <source>BMC Bioinform.</source><year>2019</year>, <volume>20</volume>, <fpage>521</fpage><pub-id pub-id-type="doi">10.1186/s12859-019-3135-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Neves</surname><given-names>B. J.</given-names></name>; <name><surname>Braga</surname><given-names>R. C.</given-names></name>; <name><surname>Melo-Filho</surname><given-names>C. C.</given-names></name>; <name><surname>Moreira-Filho</surname><given-names>J. T.</given-names></name>; <name><surname>Muratov</surname><given-names>E. N.</given-names></name>; <name><surname>Andrade</surname><given-names>C. H.</given-names></name><article-title>QSAR-Based Virtual
Screening: Advances
and Applications in Drug Discovery</article-title>. <source>Front. Pharm.</source><year>2018</year>, <volume>9</volume>, <fpage>1275</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01275</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Liu</surname><given-names>R.</given-names></name>; <name><surname>So</surname><given-names>S. S.</given-names></name><article-title>Development of quantitative
structure-property relationship models
for early ADME evaluation in drug discovery. 1. Aqueous solubility</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>2001</year>, <volume>41</volume>, <fpage>1633</fpage>–<lpage>1639</lpage>. <pub-id pub-id-type="doi">10.1021/ci010289j</pub-id>.<pub-id pub-id-type="pmid">11749590</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Clark</surname><given-names>R. D.</given-names></name>; <name><surname>Daga</surname><given-names>P. R.</given-names></name><article-title>Building a Quantitative
Structure-Property Relationship
(QSPR) Model</article-title>. <source>Methods Mol. Biol.</source><year>2019</year>, <volume>1939</volume>, <fpage>139</fpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9089-4_8</pub-id>.<pub-id pub-id-type="pmid">30848460</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Sharp</surname><given-names>T.</given-names></name>; <name><surname>Barnes</surname><given-names>N. M.</given-names></name><article-title>Central 5-HT receptors
and their function; present
and future</article-title>. <source>Neuropharmacology.</source><year>2020</year>, <volume>177</volume>, <elocation-id>108155</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108155</pub-id>.<pub-id pub-id-type="pmid">32522572</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Rudnick</surname><given-names>G.</given-names></name>; <name><surname>Sandtner</surname><given-names>W.</given-names></name><article-title>Serotonin transport
in the 21st century</article-title>. <source>J. Gen Physiol.</source><year>2019</year>, <volume>151</volume> (<issue>11</issue>), <fpage>1248</fpage>–<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.201812066</pub-id>.<pub-id pub-id-type="pmid">31570504</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Newman-Tancredi</surname><given-names>A.</given-names></name>; <name><surname>Depoortère</surname><given-names>R. Y.</given-names></name>; <name><surname>Kleven</surname><given-names>M. S.</given-names></name>; <name><surname>Kołaczkowski</surname><given-names>M.</given-names></name>; <name><surname>Zimmer</surname><given-names>L.</given-names></name><article-title>Translating biased agonists from molecules to medications:
Serotonin 5-HT1A receptor functional selectivity for CNS disorders</article-title>. <source>Pharmacol Ther.</source><year>2022</year>, <volume>229</volume>, <elocation-id>107937</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107937</pub-id>.<pub-id pub-id-type="pmid">34174274</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Czub</surname><given-names>N.</given-names></name>; <name><surname>Szlęk</surname><given-names>J.</given-names></name>; <name><surname>Pacławski</surname><given-names>A.</given-names></name>; <name><surname>Klimończyk</surname><given-names>K.</given-names></name>; <name><surname>Puccetti</surname><given-names>M.</given-names></name>; <name><surname>Mendyk</surname><given-names>A.</given-names></name><article-title>Artificial
Intelligence-Based Quantitative
Structure-Property Relationship Model for Predicting Human Intestinal
Absorption of Compounds with Serotonergic Activity</article-title>. <source>Mol. Pharmaceutics</source><year>2023</year>, <volume>20</volume> (<issue>5</issue>), <fpage>2545</fpage>–<lpage>2555</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c01117</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="weblink" id="cit11">NovaDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dnastar.com/software/nova-protein-modeling/novadock/">https://www.dnastar.com/software/nova-protein-modeling/novadock/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="weblink" id="cit12">AutoDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="weblink" id="cit13">VEGA
QSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/about-vegahub/">https://www.vegahub.eu/about-vegahub/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="weblink" id="cit14">QSAR
TOOLBOX. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qsartoolbox.org/">https://qsartoolbox.org/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Ambure</surname><given-names>P.</given-names></name>; <name><surname>Halder</surname><given-names>A. K.</given-names></name>; <name><surname>Gonzalez Diaz</surname><given-names>H.</given-names></name>; <name><surname>Cordeiro</surname><given-names>M. N. D. S.</given-names></name><article-title>QSAR-Co: An
Open Source Software for Developing Robust Multitasking or Multitarget
Classification-Based QSAR Models</article-title>. <source>J. Chem. Inf
Model.</source><year>2019</year>, <volume>59</volume> (<issue>6</issue>), <fpage>2538</fpage>–<lpage>2544</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00295</pub-id>.<pub-id pub-id-type="pmid">31083984</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="weblink" id="cit16">PharmQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pharmacelera.com/pharmqsar/">https://pharmacelera.com/pharmqsar/</uri>, (accessed October 25, 2023).</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Guariento</surname><given-names>S.</given-names></name>; <name><surname>Franchini</surname><given-names>S.</given-names></name>; <name><surname>Tonelli</surname><given-names>M.</given-names></name>; et al. <article-title>Exhaustive CoMFA and
CoMSIA analyses around different chemical entities: a ligand-based
study exploring the affinity and selectivity profiles of 5-HT1A ligands</article-title>. <source>J. Enzyme Inhib Med. Chem.</source><year>2017</year>, <volume>32</volume> (<issue>1</issue>), <fpage>214</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2016.1247057</pub-id>.<pub-id pub-id-type="pmid">28114832</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18">AiQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/portfolio-item/aiqsar/">https://www.vegahub.eu/portfolio-item/aiqsar/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kausar</surname><given-names>S.</given-names></name>; <name><surname>Falcao</surname><given-names>A. O.</given-names></name><article-title>An automated framework for QSAR model building</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s13321-017-0256-5</pub-id>.<pub-id pub-id-type="pmid">29340790</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20">The GNU
General Public License, Version 3, 29 June <year>2007</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gnu.org/licenses/gpl-3.0.html">https://www.gnu.org/licenses/gpl-3.0.html</uri> (accessed July 5, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>ZINC—A free
database of commercially available
compounds for virtual screening</article-title>. <source>J. Chem. Inf.
Model.</source><year>2005</year>, <volume>45</volume>, <fpage>177</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id>.<pub-id pub-id-type="pmid">15667143</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M. P.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; et al. <article-title>ChEMBL: Towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume>, <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Cruz</surname><given-names>A.</given-names></name>; <name><surname>Ramsey</surname><given-names>S.</given-names></name>; et al. <article-title>Hidden bias in the DUD-E
dataset leads to misleading performance of deep learning in structure-based
virtual screening</article-title>. <source>PLoS One.</source><year>2019</year>, <volume>14</volume> (<issue>8</issue>), <elocation-id>e0220113</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0220113</pub-id>.<pub-id pub-id-type="pmid">31430292</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Miao</surname><given-names>R.</given-names></name>; <name><surname>Xia</surname><given-names>L. Y.</given-names></name>; <name><surname>Chen</surname><given-names>H. H.</given-names></name>; et al. <article-title>Improved Classification
of Blood-Brain-Barrier Drugs Using Deep Learning</article-title>. <source>Sci. Rep</source><year>2019</year>, <volume>9</volume>, <fpage>8802</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-44773-4</pub-id>.<pub-id pub-id-type="pmid">31217424</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="undeclared" id="cit25">Online chemical
database with modeling environment. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ochem.eu/home/show.do">https://ochem.eu/home/show.do</uri> (accessed July 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Moriwaki</surname><given-names>H.</given-names></name>; <name><surname>Tian</surname><given-names>Y. S.</given-names></name>; <name><surname>Kawashita</surname><given-names>N.</given-names></name>; <name><surname>Takagi</surname><given-names>T.</given-names></name><article-title>Mordred: A molecular
descriptor calculator</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id>.<pub-id pub-id-type="pmid">29411163</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="undeclared" id="cit27"><person-group person-group-type="allauthors"><name><surname>Plonska</surname><given-names>A.</given-names></name>; <name><surname>Plonski</surname><given-names>P.</given-names></name></person-group><article-title>MLJAR: State-of-the-Art
Automated Machine Learning Framework for Tabular Data</article-title>, version 0.10.3. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mljar/mljar-supervised">https://github.com/mljar/mljar-supervised</uri>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="weblink" id="cit28">Guidance
Document on the Validation of (Quantitative) Structure-Activity Relationship
[(Q)SAR] Models. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm">https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Pälvimäki</surname><given-names>E. P.</given-names></name>; et al. <article-title>Interactions of selective serotonin reuptake inhibitors with the
serotonin 5-HT2C receptor</article-title>. <source>Psychopharmacology</source><year>1996</year>, <volume>126</volume>, <fpage>234</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1007/BF02246453</pub-id>.<pub-id pub-id-type="pmid">8876023</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Shapiro</surname><given-names>D. A.</given-names></name>; et al. <article-title>Aripiprazole, a novel
atypical antipsychotic drug with a unique and
robust pharmacology</article-title>. <source>Neuropsychopharmacology.</source><year>2003</year>, <volume>28</volume> (<issue>8</issue>), <fpage>1400</fpage>–<lpage>1411</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300203</pub-id>.<pub-id pub-id-type="pmid">12784105</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="weblink" id="cit31">Santa
Cruz. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scbt.com/p/zolmitriptan-139264-17-8">https://www.scbt.com/p/zolmitriptan-139264-17-8</uri> (accessed November
22, 2023).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Cosi</surname><given-names>C.</given-names></name>; <name><surname>Koek</surname><given-names>W.</given-names></name><article-title>Agonist, antagonist,
and inverse agonist properties of antipsychotics
at human recombinant 5-HT<sub>1A</sub> receptors expressed in HeLa
cells</article-title>. <source>Eur. J. Pharmacol.</source><year>2001</year>, <volume>433</volume> (<issue>1</issue>), <fpage>55</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(01)01493-5</pub-id>.<pub-id pub-id-type="pmid">11755134</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Kaplan</surname><given-names>A. L.</given-names></name>; <name><surname>Confair</surname><given-names>D. N.</given-names></name>; <name><surname>Kim</surname><given-names>K.</given-names></name>; et al. <article-title>Bespoke library docking
for 5-HT2A receptor agonists with antidepressant activity</article-title>. <source>Nature.</source><year>2022</year>, <volume>610</volume>, <fpage>582</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05258-z</pub-id>.<pub-id pub-id-type="pmid">36171289</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sparaco</surname><given-names>R.</given-names></name>; <name><surname>Kędzierska</surname><given-names>E.</given-names></name>; <name><surname>Kaczor</surname><given-names>A. A.</given-names></name>; <name><surname>Bielenica</surname><given-names>A.</given-names></name>; <name><surname>Magli</surname><given-names>E.</given-names></name>; <name><surname>Severino</surname><given-names>B.</given-names></name>; <name><surname>Corvino</surname><given-names>A.</given-names></name>; <name><surname>Gibuła-Tarłowska</surname><given-names>E.</given-names></name>; <name><surname>Kotlińska</surname><given-names>J. H.</given-names></name>; <name><surname>Andreozzi</surname><given-names>G.</given-names></name>; et al. <article-title>Synthesis, Docking Studies
and Pharmacological Evaluation of Serotoninergic Ligands Containing
a 5-Norbornene-2-Carboxamide Nucleus</article-title>. <source>Molecules.</source><year>2022</year>, <volume>27</volume> (<issue>19</issue>), <fpage>6492</fpage><pub-id pub-id-type="doi">10.3390/molecules27196492</pub-id>.<pub-id pub-id-type="pmid">36235029</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Levit
Kaplan</surname><given-names>A.</given-names></name>; <name><surname>Strachan</surname><given-names>R. T.</given-names></name>; <name><surname>Braz</surname><given-names>J. M.</given-names></name>; <name><surname>Craik</surname><given-names>V.</given-names></name>; <name><surname>Slocum</surname><given-names>S.</given-names></name>; <name><surname>Mangano</surname><given-names>T.</given-names></name>; <name><surname>Amabo</surname><given-names>V.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H.</given-names></name>; <name><surname>Lak</surname><given-names>P.</given-names></name>; <name><surname>Basbaum</surname><given-names>A. I.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Structure-Based
Design of a Chemical Probe Set for the 5-HT5A Serotonin Receptor</article-title>. <source>J. Med. Chem.</source><year>2022</year>, <volume>65</volume> (<issue>5</issue>), <fpage>4201</fpage>–<lpage>4217</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02031</pub-id>.<pub-id pub-id-type="pmid">35195401</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Łażewska</surname><given-names>D.</given-names></name>; <name><surname>Więcek</surname><given-names>M.</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>Chałupnik</surname><given-names>P.</given-names></name>; <name><surname>Żesławska</surname><given-names>E.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Tarasek</surname><given-names>M.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Szymańska</surname><given-names>E.</given-names></name>; et al. <article-title>New Triazine Derivatives as Serotonin
5-HT6 Receptor Ligands</article-title>. <source>Molecules.</source><year>2023</year>, <volume>28</volume> (<issue>3</issue>), <fpage>1108</fpage><pub-id pub-id-type="doi">10.3390/molecules28031108</pub-id>.<pub-id pub-id-type="pmid">36770774</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Czarnota-Łydka</surname><given-names>K.</given-names></name>; <name><surname>Sudoł-Tałaj</surname><given-names>S.</given-names></name>; <name><surname>Kucwaj-Brysz</surname><given-names>K.</given-names></name>; <name><surname>Kurczab</surname><given-names>R.ł</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>de Candia</surname><given-names>M.</given-names></name>; <name><surname>Samarelli</surname><given-names>F.</given-names></name>; <name><surname>Altomare</surname><given-names>C. D.</given-names></name>; <name><surname>Carocci</surname><given-names>A.</given-names></name>; <name><surname>Barbarossa</surname><given-names>A.</given-names></name>; <name><surname>Zesławska</surname><given-names>E.</given-names></name>; <name><surname>Głuch-Lutwin</surname><given-names>M.</given-names></name>; <name><surname>Mordyl</surname><given-names>B.</given-names></name>; <name><surname>Kubacka</surname><given-names>M.</given-names></name>; <name><surname>Wilczynska-Zawal</surname><given-names>N.</given-names></name>; <name><surname>Jastrzebska-Wiesek</surname><given-names>M.</given-names></name>; <name><surname>Partyka</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>N.</given-names></name>; <name><surname>Wiecek</surname><given-names>M.łg.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Wesołowska</surname><given-names>A.</given-names></name>; <name><surname>Carrieri</surname><given-names>A.</given-names></name>; <name><surname>Handzlik</surname><given-names>J.</given-names></name><article-title>Synthesis,
computational and experimental pharmacological studies for (thio)ether-triazine
5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent
intrinsic activity in search for new class of drugs against Alzheimer’s
disease</article-title>. <source>Eur. J. Med. Chem.</source><year>2023</year>, <volume>259</volume>, <fpage>115695</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115695</pub-id>.<pub-id pub-id-type="pmid">37567058</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Penjisevic</surname><given-names>J. Z.</given-names></name>; <name><surname>Sukalovic</surname><given-names>V. B.</given-names></name>; <name><surname>Dukic-Stefanovic</surname><given-names>S.</given-names></name>; <name><surname>Deuther-Conrad</surname><given-names>W.</given-names></name>; <name><surname>Andric</surname><given-names>D. B.</given-names></name>; <name><surname>Kostic-Rajacic</surname><given-names>S.đa.
V.</given-names></name><article-title>Synthesis of novel 5-HT1A
arylpiperazine ligands: Binding data and computer-aided analysis of
pharmacological potency</article-title>. <source>Arab. J. Chem.</source><year>2023</year>, <volume>16</volume>, <fpage>104636</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2023.104636</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><person-group person-group-type="allauthors"><name><surname>Shapley</surname><given-names>L. S.</given-names></name></person-group><article-title>A Value for
N-Person Games</article-title>. <publisher-name>RAND Corporation</publisher-name>: <publisher-loc>Santa Monica, CA</publisher-loc>, <year>1952</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rand.org/pubs/papers/P295.html">https://www.rand.org/pubs/papers/P295.html</uri>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="undeclared" id="cit40"><person-group><name><surname>Lundberg</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>S. I.</given-names></name></person-group><article-title>A Unified Approach to Interpreting
Model Predictions</article-title>. <source>ArXiv Preprint</source>, arXiv:1705.07874, <year>2017</year>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="undeclared" id="cit41"><person-group person-group-type="allauthors"><name><surname>Szlęk</surname><given-names>J.</given-names></name></person-group><article-title>Model
Interpretation</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/jszlek/MODEL_INTERPRETATION">https://github.com/jszlek/MODEL_INTERPRETATION</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="weblink" id="cit42">Steamlit:
a faster way to build and share data apps. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://streamlit.io/">https://streamlit.io/</uri> (accessed
June 2, 2023).</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Sivandzade</surname><given-names>F.</given-names></name>; <name><surname>Cucullo</surname><given-names>L.</given-names></name><article-title>In-vitro blood-brain
barrier modeling: A review of
modern and fast-advancing technologies</article-title>. <source>J. Cereb
Blood Flow Metab.</source><year>2018</year>, <volume>38</volume> (<issue>10</issue>), <fpage>1667</fpage>–<lpage>1681</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X18788769</pub-id>.<pub-id pub-id-type="pmid">30058456</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="weblink" id="cit44">Canva. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/">https://www.canva.com/</uri> (accessed
10 June 2023).</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="undeclared" id="cit45a">Streamlit
ketcher. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io">https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io</uri> (accessed July 15, 2023).</mixed-citation>
      <mixed-citation publication-type="journal" id="cit45b"><name><surname>Abuhelwa</surname><given-names>A. Y.</given-names></name>; <name><surname>Williams</surname><given-names>D. B.</given-names></name>; <name><surname>Upton</surname><given-names>R. N.</given-names></name>; <name><surname>Foster</surname><given-names>D. J.</given-names></name><article-title>Food, gastrointestinal pH, and models of oral drug
absorption</article-title>. <source>Eur. J. Pharm. Biopharm.</source><year>2017</year>, <volume>112</volume>, <fpage>234</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2016.11.034</pub-id>.<pub-id pub-id-type="pmid">27914234</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11005036</article-id>
    <article-id pub-id-type="pmid">38289046</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01517</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SerotoninAI: Serotonergic
System Focused, Artificial
Intelligence-Based Application for Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6660-4446</contrib-id>
        <name>
          <surname>Łapińska</surname>
          <given-names>Natalia</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2801-6197</contrib-id>
        <name>
          <surname>Pacławski</surname>
          <given-names>Adam</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1537-9650</contrib-id>
        <name>
          <surname>Szlęk</surname>
          <given-names>Jakub</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4394-9115</contrib-id>
        <name>
          <surname>Mendyk</surname>
          <given-names>Aleksander</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Pharmaceutical Technology and Biopharmaceutics, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
      <aff id="aff2"><label>‡</label>Doctoral
School of Medicinal and Health Sciences, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.szlek@uj.edu.pl</email>. Tel.: <phone>+48-(12)-6205604</phone>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>7</issue>
    <issue-title>Machine
Learning in Bio-cheminformatics</issue-title>
    <fpage>2150</fpage>
    <lpage>2157</lpage>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>09</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>01</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>01</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0004" id="ab-tgr1"/>
      </p>
      <p>SerotoninAI is an innovative web application for scientific
purposes
focused on the serotonergic system. By leveraging SerotoninAI, researchers
can assess the affinity (pKi value) of a molecule to all main serotonin
receptors and serotonin transporters based on molecule structure introduced
as SMILES. Additionally, the application provides essential insights
into critical attributes of potential drugs such as blood–brain
barrier penetration and human intestinal absorption. The complexity
of the serotonergic system demands advanced tools for accurate predictions,
which is a fundamental requirement in drug development. SerotoninAI
addresses this need by providing an intuitive user interface that
generates predictions of pKi values for the main serotonergic targets.
The application is freely available on the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://serotoninai.streamlit.app/">https://serotoninai.streamlit.app/</uri>, implemented in Streamlit with all major web browsers supported.
Currently, to the best of our knowledge, there is no tool that allows
users to access affinity predictions for serotonergic targets without
registration or financial obligations. SerotoninAI significantly increases
the scope of drug development activities worldwide. The source code
of the application is available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Uniwersytet Jagiellonski Collegium Medicum</institution>
            <institution-id institution-id-type="doi">10.13039/100009045</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>7N42/DBS/000205</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>The rise and development
of artificial intelligence (AI) tools
have a revolutionary impact on many areas of science and industry.
In the field of drug design, AI is showing the potential to change
traditional approaches, enabling faster and more efficient discovery
and development of new therapeutic agents.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> One
of the benefits of AI is the development of advanced QSAR (quantitative
structure–activity relationship) and QSPR (quantitative structure–property
relationship) models. Their ability to screen new active compounds,
possible side effects, bioavailability and other properties can speed
up and increase cost effectiveness both of the drug discovery and
development phases.<sup><xref ref-type="bibr" rid="ref3">3</xref>−<xref ref-type="bibr" rid="ref6">6</xref></sup></p>
    <p>Our work focuses on serotonin receptors and transporters.
Selected
biological targets are important for many drugs that impact the central
nervous system (CNS). Substances that affect the serotonergic system
are used to treat mood, migraine, regulate sleep, and treat neurotic
disorders or eating disorders. Furthermore, recent studies show that
they can improve cognitive function. Preliminary studies also show
that they may represent an even broader spectrum of therapeutic applications
than CNS activity. For example, the serotonin 5-HT2C receptor has
a role in impulse control, and the 5-HT3 receptor plays a role in
controlling nausea and vomiting.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref></sup></p>
    <p>SerotoninAI is an application
focused on compounds with a serotonergic
activity. It allows predictions of affinity for various 5-HT receptors
as well as the serotonin transporter. The affinity for a selected
biological target ensures a potential application of a molecule as
a future drug and allows us to anticipate possible side effects. Moreover,
SerotoninAI predicts human intestinal absorption (HIA) and blood–brain
barrier (BBB) penetration of the given chemical structure. For the
molecule, a confirmed BBB penetration is a crucial property for drugs
acting on the central nervous system, whereas extensive HIA ensures
feasibility of the oral administration route, the most preferred and
acceptable one in the therapy. The artificial intelligence (AI)-based
system for HIA has been developed on data sets with serotonergic ligands,
which limits its application to these molecules only.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></p>
    <p>There are a number of ready-to-use programs for assessing
protein–molecule
interactions which the main task is to dock molecules in the corresponding
protein, such as NovaDock<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and AutoDock.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> On the other hand, VEGA QSAR<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and QSAR TOOLBOX<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> do not provide
predictions of affinity for selected receptors. Their application
focuses on physical and chemical properties and also ADME-TOX properties.
In contrast, typical QSAR models are provided by applications such
as QSAR-Co<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and PharmQSAR.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> In the case of QSAR-Co, the prediction capabilities
are limited to classification models. Moreover, to obtain predictions,
the user needs to download and run the tool’s own machine,
which might introduce some difficulties related to OS/machine specification.
Moreover, the authors of the application do not provide ready-to-use
models related to the serotonin system. PharmQSAR allows the creation
of statistical models using techniques CoMFA (Comparative Molecular
Field Analysis) and CoMSIA (Comparative Molecular Similarity Indices
Analysis)<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> and also does not provide models
for serotonin receptors and transporters. In the aforementioned applications
for QSAR models, whether ready-made or with the ability to create
them, registration is required, which greatly limits the use of such
an application. Provided preliminary limitations for users prevent
us from directly comparing the presented systems with our models.</p>
    <p>The only tool available without registration that provides QSAR
models is aiQSAR.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> In order to use the
ready-made models, we need to download the applications to our own
machine. However, among the 38 biological targets, there is none related
to the serotonin system. A publication describing QSAR models for
serotonin receptors is the work of Kausar et al.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> They describe the results for most serotonin receptors,
but we have no way of comparing the results because databases are
not available (no information about training and test set beyond the
number of molecules). When considering the available tools, we decided
to create SerotoninAI as the missing piece to accelerate the drug
discovery process.</p>
    <p>SerotoninAI as a web-based app allows users
to easily obtain predictions
for chosen molecules without the need for installing any tools on
their own computers, as well as without any programming skills. To
the best of our knowledge, SerotoninAI is the first affinity prediction
tool for serotonin targets without mandatory registration of a user.
Moreover, the only information needed from the user side is SMILES
(Simplified Molecular Input Line Entry Specification) of a molecule.
It is worth mentioning that the application is distributed under the
GNU General Public License version 3<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> and
the source code is provided on the GitHub platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>).</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Results and Discussion</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Databases</title>
      <p>The application uses QSAR
models developed on data extracted from two leading databases, namely,
ZINC and ChEMBL (data extracted in December 2022).<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> Data were acquired for each target involving serotonergic activity,
that is, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4,
5-HT5A, 5-HT6, 5-HT7, and the serotonin transporter SERT. Despite
the presence of ligands for 5-HT1E and 5-HT1F as well as 5-HT5B receptors
these databases were not used to create models due to their small
size (&lt;500 molecules) resulting in the limited applicability domain.
Our approach was to provide models based only on the experimentally
validated data; therefore, no decoys were used in any of the training
or testing data sets.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>
      <p>The dependent
variable was the value of ligand affinity presented as the negative
logarithm of the inhibition constant, the pKi value. In the data preparation
part, duplicates were first removed from the ZINC and ChEMBL databases
separately, and invalid SMILES were removed. No other specific structure
curation was employed. The two databases were then merged, and some
molecules were present in both databases. Molecule pairs with a pKi
difference greater than 0.1 were removed from the database. In the
group of molecule pairs with a pKi difference equal to or less than
0.1, the ZINC molecule was selected as the reference substance. The
databases were randomly divided into training and test sets at a ratio
of 80:20. The former part of the data (80%) was used to develop QSAR
models according to the 10-fold cross validation scheme, and the latter
(20%) was used as an external test set. <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> shows histograms of pKi values for each
biological target according to the training and test set.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Histograms
of the pKi values: (A) 5-HT1A serotonin receptor. (B)
5-HT1B serotonin receptor. (C) 5-HT1D serotonin receptor. (D) 5-HT2A
serotonin receptor. (E) 5-HT2B serotonin receptor. (F) 5-HT2C serotonin
receptor. (G) 5-HT3 serotonin receptor. (H) 5-HT4 serotonin receptor.
(I) 5-HT5A serotonin receptor. (J) 5-HT6 serotonin receptor. (K) 5-HT7
serotonin receptor. (L) Serotonin transporter SERT.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0001" id="gr1" position="float"/>
      </fig>
      <p>The database for predicting HIA was described in
our previous work;<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> the source of the
data was literature data and
the ChEMBL database.</p>
      <p>QSPR classification model of BBB permeability
was based on the
database collected from the work of Miao et al.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> (data set 1 and data set 2) and enriched by us with data
from OCHEM database<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> (data extracted in
July 2023). It resulted in 2853 molecules in the training set. An
independent test set from the article by Miao et al. remained in the
test set of our experiment (161 molecules) in order to better compare
our developed QSPR model.</p>
      <p>All data are available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">Supporting Information</ext-link> as a single database.zip
file containing separate training/test
csv files for each respective biological target.</p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Molecular Representation</title>
      <p>Mordred
descriptors were used as a molecular representation of chemical structures.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Mordred effectiveness in this field and suitability
for interpretation has been tested in our previous work.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> QSAR and QSPR models were created based on two-dimensional
descriptors to prevent the risk of variability in three-dimensional
descriptors due to nonconvergent molecules’ optimization. Based
on SMILES, SerotoninAI automatically creates the molecular descriptors
required by the models.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>QSAR and QSPR Models</title>
      <p>Modeling was
performed with the mljar-supervised tool, which belongs to the field
of Automated Machine Learning (AutoML).<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> In the case of receptors, serotonin transporter and BBB permeability
models were de novo created for the purpose of the presented application.
On the other hand, for human intestinal absorption, the AI-based system
has already been published<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and has been
implemented in this application without any further modifications.</p>
      <p>QSAR regression models were created according to the 10-fold cross-validation
scheme (10-CV) on 80% of the curated databases. For each target, about
2000 models were developed. We used root-mean-square error (RMSE)
and coefficient of determination (<italic>R</italic><sup>2</sup>)
values to evaluate and select the best models (<xref rid="eq1" ref-type="disp-formula">eqs <xref rid="eq1" ref-type="disp-formula">1</xref></xref> and <xref rid="eq2" ref-type="disp-formula">2</xref>), in accordance
with the guidelines of the Organization for Economic Co-operation
and Development’s QSAR models.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The results were analyzed for the training set (10-CV) and the separate
test set (20%). In <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, we show the detailed results for each QSAR model.<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m001" position="anchor"/><label>1</label></disp-formula>where RMSE = root-mean-square
error, obs<sub><italic>i</italic></sub> and pred<sub><italic>i</italic></sub> = observed and predicted values, <italic>i</italic> = data
record number, and <italic>n</italic> = total number of records.<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m002" position="anchor"/><label>2</label></disp-formula>where <italic>R</italic><sup>2</sup> = the coefficient of determination, SS<sub>res</sub> = the
sum of squares of the residual errors, S<italic>S</italic><sub>tot</sub> = the total sum of the errors, obs<sub><italic>i</italic></sub> and
pred<sub><italic>i</italic></sub> = observed and predicted values,
and obs = arithmetical mean of observed values.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Number of Ligands for Each Target,
Number of Descriptors Used for QSAR Models after Removing Constant
and Highly Correlated Variables, Results for Training Set and Test
Set, and Type of Each Model of QSAR Models</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Number of ligands</th>
              <th style="border:none;" align="center">Number of descriptors</th>
              <th style="border:none;" align="center">RMSE 10-CV</th>
              <th style="border:none;" align="center">R<sup>2</sup> 10-CV</th>
              <th style="border:none;" align="center">RMSE test</th>
              <th style="border:none;" align="center">R<sup>2</sup> test</th>
              <th style="border:none;" align="center">Model type</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">10,175</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.555</td>
              <td style="border:none;" align="center">0.733</td>
              <td style="border:none;" align="center">0.629</td>
              <td style="border:none;" align="center">0.660</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">1833</td>
              <td style="border:none;" align="center">710</td>
              <td style="border:none;" align="center">0.627</td>
              <td style="border:none;" align="center">0.731</td>
              <td style="border:none;" align="center">0.558</td>
              <td style="border:none;" align="center">0.805</td>
              <td style="border:none;" align="center">Ensemble model (5x Xgboost, 4x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">2072</td>
              <td style="border:none;" align="center">739</td>
              <td style="border:none;" align="center">0.566</td>
              <td style="border:none;" align="center">0.836</td>
              <td style="border:none;" align="center">0.536</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">Ensemble model (5x
Xgboost, 4x LightGBM, 2x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6926</td>
              <td style="border:none;" align="center">703</td>
              <td style="border:none;" align="center">0.582</td>
              <td style="border:none;" align="center">0.769</td>
              <td style="border:none;" align="center">0.567</td>
              <td style="border:none;" align="center">0.764</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">2821</td>
              <td style="border:none;" align="center">723</td>
              <td style="border:none;" align="center">0.561</td>
              <td style="border:none;" align="center">0.674</td>
              <td style="border:none;" align="center">0.607</td>
              <td style="border:none;" align="center">0.608</td>
              <td style="border:none;" align="center">Ensemble model (6x Xgboost, 2x LightGBM, 5x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">5097</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">0.625</td>
              <td style="border:none;" align="center">0.673</td>
              <td style="border:none;" align="center">0.603</td>
              <td style="border:none;" align="center">0.685</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">562</td>
              <td style="border:none;" align="center">665</td>
              <td style="border:none;" align="center">0.837</td>
              <td style="border:none;" align="center">0.672</td>
              <td style="border:none;" align="center">0.867</td>
              <td style="border:none;" align="center">0.680</td>
              <td style="border:none;" align="center">Ensemble model (2x Xgboost, 3x CatBoost, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT4</td>
              <td style="border:none;" align="center">949</td>
              <td style="border:none;" align="center">516</td>
              <td style="border:none;" align="center">0.682</td>
              <td style="border:none;" align="center">0.753</td>
              <td style="border:none;" align="center">0.690</td>
              <td style="border:none;" align="center">0.697</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.575</td>
              <td style="border:none;" align="center">0.797</td>
              <td style="border:none;" align="center">0.568</td>
              <td style="border:none;" align="center">0.761</td>
              <td style="border:none;" align="center">Ensemble model (3x Xgboost, 3x CatBoost,
1x ExtraTrees, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">5925</td>
              <td style="border:none;" align="center">688</td>
              <td style="border:none;" align="center">0.579</td>
              <td style="border:none;" align="center">0.777</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.749</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">4411</td>
              <td style="border:none;" align="center">727</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.684</td>
              <td style="border:none;" align="center">0.601</td>
              <td style="border:none;" align="center">0.728</td>
              <td style="border:none;" align="center">CatBoost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8091</td>
              <td style="border:none;" align="center">541</td>
              <td style="border:none;" align="center">0.490</td>
              <td style="border:none;" align="center">0.851</td>
              <td style="border:none;" align="center">0.492</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>, we have
presented examples of drugs available on the market along with their
affinities from literature sources and pKi values predicted by the
SerotoninAI.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>SerotoninAI’s Predictions and
Literature Values of pKi for Drug Examples Related to Serotonergic
System</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Drug</th>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Experimental/Literature pKi value</th>
              <th style="border:none;" align="center">SerotoninAI
prediction</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Fluoxetine<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></td>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6.150</td>
              <td style="border:none;" align="center">6.631</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.371</td>
              <td style="border:none;" align="center">6.308</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8.708</td>
              <td style="border:none;" align="center">8.013</td>
            </tr>
            <tr>
              <td rowspan="11" style="border:none;" align="center">Aripiprazole<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">8.252</td>
              <td style="border:none;" align="center">7.527</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">6.081</td>
              <td style="border:none;" align="center">5.913</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">7.167</td>
              <td style="border:none;" align="center">6.753</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">8.060</td>
              <td style="border:none;" align="center">8.366</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">9.444</td>
              <td style="border:none;" align="center">7.982</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.119</td>
              <td style="border:none;" align="center">7.195</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">6.202</td>
              <td style="border:none;" align="center">6.160</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">5.907</td>
              <td style="border:none;" align="center">5.890</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">6.244</td>
              <td style="border:none;" align="center">6.716</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">7.987</td>
              <td style="border:none;" align="center">7.570</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">5.967</td>
              <td style="border:none;" align="center">6.646</td>
            </tr>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Zolmitriptan<sup><xref ref-type="bibr" rid="ref31">31</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">7.105</td>
              <td style="border:none;" align="center">6.562</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">8.377</td>
              <td style="border:none;" align="center">8.089</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">9.199</td>
              <td style="border:none;" align="center">8.733</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Clozapine<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">6.990</td>
              <td style="border:none;" align="center">6.357</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The examples presented above are also included in
curated databases
prepared to create QSAR models, which do not constitute the usefulness
of such a model for unseen examples of molecules. Therefore, we decided
to test the created models on the latest available data. For this
purpose, we reviewed the literature from 2022, when the first databases
were created. New experimental data were available for seven biological
targets (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and
5-HT7).<sup><xref ref-type="bibr" rid="ref33">33</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> In <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>, we present
summary results for each receptor and the sum of predictions, using
SerotoninAI, located in four categories: when the prediction difference
was less than 0.5, greater than or equal to 0.5 and less than 1.0,
the third group being prediction differences equal to or greater than
1.0 and less than 2.0, and the last group indicating a very large
prediction difference, a value equal to or greater than 2.0. All predictions
are available in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">Supporting Information S1</ext-link>. The worst predictions are seen for the 5-HT5A receptor. In our
opinion, this is due to too little differentiated data. Of the seven
targets for which external data were available, the database for the
5-HT5A receptor was the smallest (720 molecules).</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Summary of pKi Pedictions by SerotoninAI
for New Experimental Data Available in the Literature in the Years
2022–2023</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th colspan="4" align="center">Differences
of literature data and SerotoninAI predictions of pKi<hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">receptor</th>
              <th style="border:none;" align="center">&lt;0.5</th>
              <th style="border:none;" align="center">≥0.5 and &lt;1.0</th>
              <th style="border:none;" align="center">≥1.0 and &lt;2.0</th>
              <th style="border:none;" align="center">≥2.0</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">2</td>
              <td style="border:none;" align="center">13</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">31</td>
              <td style="border:none;" align="center">15</td>
              <td style="border:none;" align="center">6</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">3</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">4</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">24</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">8</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">23</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">total</td>
              <td style="border:none;" align="center">102</td>
              <td style="border:none;" align="center">44</td>
              <td style="border:none;" align="center">38</td>
              <td style="border:none;" align="center">8</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The QSPR model for BBB penetration was a binary classification
model (1, molecule penetrates to brain; 0, no penetration). It was
also created according to 10-CV. To evaluate the model, classification
metrics like accuracy, precision, recall, F1 score, and Matthews correlation
coefficient (MCC) were used (<xref rid="eq3" ref-type="disp-formula">eqs <xref rid="eq3" ref-type="disp-formula">3</xref></xref>–<xref rid="eq7" ref-type="disp-formula">7</xref>). These results and confusion
matrices for the training and test set are shown in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> and <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>. We compared our results on the test set
with the recent article on BBB penetration,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and our model resulted in more accurate predictions. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">Supporting Information S2</ext-link> provides a detailed
description of these results.<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m004" position="anchor"/><label>4</label></disp-formula><disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m005" position="anchor"/><label>5</label></disp-formula><disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m006" position="anchor"/><label>6</label></disp-formula>where TP = true positive, TN = true negative,
FP = false positive, and FN = false negative.<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m007" position="anchor"/><label>7</label></disp-formula></p>
      <table-wrap id="tbl4" position="float">
        <label>Table 4</label>
        <caption>
          <title>Summary of Classification Metrics
for Training and Test Set for the Blood–Brain Barrier Penetration
Model</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center">Training set (10-CV)</th>
              <th style="border:none;" align="center">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">Accuracy</td>
              <td style="border:none;" align="center">0.94</td>
              <td style="border:none;" align="center">0.87</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Precision</td>
              <td style="border:none;" align="center">1.00</td>
              <td style="border:none;" align="center">0.80</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Recall</td>
              <td style="border:none;" align="center">0.91</td>
              <td style="border:none;" align="center">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">F1 score</td>
              <td style="border:none;" align="center">0.96</td>
              <td style="border:none;" align="center">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Matthews correlation coefficient</td>
              <td style="border:none;" align="center">0.88</td>
              <td style="border:none;" align="center">0.76</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Number
of compounds</td>
              <td style="border:none;" align="center">2853</td>
              <td style="border:none;" align="center">161</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Type of model</td>
              <td colspan="2" align="center">Ensemble model (5x Xgboost, 7x NeuralNetwork, 2x LightGBM)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Confusion matrices for training and test sets: blood–-brain
barrier QSPR model.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0002" id="gr2" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Applicability Domain</title>
      <p>The major challenge
that researchers face in developing QSAR or QSPR models is the scarcity
of data. Based on the available data, the model predicts correctly
within the relevant ranges of descriptors. For these reasons, SerotoninAI
with each prediction provides information on whether the studied compound
is within the applicability domain (AD) or not. Naturally, within-AD
predictions are characterized with higher accuracy even though the
compound is unknown to the system, namely, beyond the training data.</p>
      <p>The AD was obtained based on the 10 most important descriptors
for each model. The importance ranking of the descriptors was obtained
using SHAP analysis. SHAP (Shapley Additive Explanations) is a method
used to explain complex AI/ML models. It is based on a concept called
the Shapley value, introduced by Lloyd Shapley in 1952.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Shapley, who was distinguished for his input
in game theory by the Nobel Memorial Prize in Economic Sciences in
2012, focused on how to fairly divide rewards from the game among
cooperating players. The solution for the analyzed problem should
allow for splitting the reward of the team among all players in a
proportional way to its contribution to the result and at the same
time fulfill criteria of efficiency, additivity, symmetry, and null
player presence detection. The unique solution for that problem is
the Shapley value which divides the reward based on each player’s
marginal contribution, ensuring fairness. In the realm of predictive
modeling, this framework can be adapted to assess the incremental
contribution of each input variable of the model to the predicted
outcome.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> In this study, we employed SHAP
analysis to examine the overarching influence of each variable, considering
both the magnitude and the direction (high or low values of the variable)
of its impact on the final prediction. This analysis was conducted
in Python environment, leveraging a framework developed by Szlęk,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> further augmented with a wrapper for the mljar
package. Summary plots of SHAP analysis for each obtained model are
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">Supporting Information S3</ext-link>,
except for the HIA model, where the entire analysis was described
in previous article.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The values of these
descriptors in the training set were transformed via Min–Max
normalization. A compound is under AD if seven descriptors are in
the range between minimum and maximum values of the training set. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> presents examples
of compounds within and outside the applicability domain.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>A comparison
of the molecule’s applicability domains. (Left)
A molecule within the applicability domain. (Right) A molecule out
of the applicability domain. The gray area indicates the application
domain.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0003" id="gr3" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.5">
      <label>2.5</label>
      <title>Application Development</title>
      <p>SerotoninAI
was developed using Streamlit, an open-source Python library that
simplifies the process of developing web applications. It enables
developers to create interactive and user-friendly web applications
using Python scripts.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Our app includes
pharmacological descriptions for each biological target and a medical
and biopharmaceutical introduction to intestinal permeability and
blood–brain barrier based on literature data.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> This enables scientists to better
understand the mechanisms of action of these receptors and identify
potential targets for new drugs. This knowledge can accelerate the
drug discovery process, enabling scientists to design compounds with
the desired pharmacological properties. The graphics page was enhanced
with images created using Canva software.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Implementation</title>
    <p>SerotoninAI operates
in several modes. The user can obtain predictions
for the target’s affinity or class of HIA and BBB, either for
a single compound or based on a collection of molecules represented
by a CSV file, the so-called batch mode. However, due to limited resources
provided by the Streamlit server, we encourage users to run batch
mode locally on their own machines. From the user’s perspective,
the model makes predictions based on SMILES, imported directly from
the DrugBank/ChEMBL/ZINC without a specific structure curation. In
the case of a CSV file, compounds should be represented in a column
named “smiles”. There is also the possibility to draw
molecules and obtain particular SMILES.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup></p>
    <p>Another feature of the application is to obtain a prediction
for
one biological target only, multiple user-selected targets, or all
of them at once. Depending on the research needs, scientists may choose
which serotonin receptors are relevant. This mode works with only
a CSV file. It is worth remembering that with more molecules and more
targets under study, the prediction time increases. The result of
the predictions for multiple molecules is a downloadable file with
ready-made predictions. As in the case of individual predictions for
a single target, information about the applicability domain appears.
In the case of batch mode, it takes the values “True”
or “False”, where “True” means that the
tested compound is in the AD defined in <xref rid="sec2.4" ref-type="other">section <xref rid="sec2.4" ref-type="other">2.4</xref></xref>.</p>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusion</title>
    <p>The developed SerotoninAI
application is publicly available AI-based
software for obtaining affinity and permeability predictions for the
intestinal wall and blood–brain barrier. The use of such predictions
for serotonin receptors and transporters can significantly accelerate
the time to find new compounds with potential pharmacological activity,
mainly in the field of central nervous system diseases. This application,
governed by the GNU General Public License version 3,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> comes with no liability from the authors for the obtained
results. The published version of the app is not password protected;
neither is the data privacy ensured. For the latter, the user must
download the source code and install the app in the controlled environment.</p>
    <p>Limitations due to the small amount of data to create models for
several serotonin receptors (5-HT1E, 5-HT1E, and 5-HT5B) will be overcome
when more data about ligands for these receptors are published. SerotoninAI
will be updated on an ongoing basis for at least 2 years when larger
databases become available and/or better predictive models can be
obtained. Due to limited resources available to streamlit applications,
batch mode computations should be run locally.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The data underlying
this study are available in the published article and its <xref rid="notes-1" ref-type="notes">Supporting Information</xref>, except the data used
for developing HIA model, which are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/HIA_5-HT">https://github.com/nczub/HIA_5-HT</uri>.</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supporting Information S1, Table 1: prediction results
of external data of ligands for seven targets of serotonin system
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S2, Table 2: prediction results
of 161 compounds, test set of blood–brain barrier model (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S3, Figure: Summary plot of SHAP
analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">PDF</ext-link>)</p></list-item><list-item><p>Databases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">ZIP</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_001.xlsx">
        <caption>
          <p>ci3c01517_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_002.xlsx">
        <caption>
          <p>ci3c01517_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_003.pdf">
        <caption>
          <p>ci3c01517_si_003.pdf</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile4">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_004.zip">
        <caption>
          <p>ci3c01517_si_004.zip</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e1139-autogenerated">
    <p>The authors declare
no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This research/study was carried out with
the use of research
infrastructure cofinanced by the Smart Growth Operational Programme
POIR 4.2 project no. POIR.04.02.00-00-D023/20. Research was partially
supported by Jagiellonian University Medical College in Kraków,
Grant Number 7N42/DBS/000205. Equipment was also cofinanced by the
qLIFE Priority Research Area under the program “Excellence
Initiative—Research University” at Jagiellonian University.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>10-CV</term>
        <def>
          <p>10-fold
cross-validation</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT</term>
        <def>
          <p>5-hydroxytryptamine,
serotonin</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1A</sub></term>
        <def>
          <p>serotonin 1A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1B</sub></term>
        <def>
          <p>serotonin 1B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1D</sub></term>
        <def>
          <p>serotonin
1D receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1E</sub></term>
        <def>
          <p>serotonin 1E receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1F</sub></term>
        <def>
          <p>serotonin 1F receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2A</sub></term>
        <def>
          <p>serotonin
2A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2B</sub></term>
        <def>
          <p>serotonin 2B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2C</sub></term>
        <def>
          <p>serotonin 2C receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>3</sub></term>
        <def>
          <p>serotonin
3 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>4</sub></term>
        <def>
          <p>serotonin 4 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5A</sub></term>
        <def>
          <p>serotonin 5A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5B</sub></term>
        <def>
          <p>serotonin 5B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>6</sub></term>
        <def>
          <p>serotonin
6 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>7</sub></term>
        <def>
          <p>serotonin 7 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>AD</term>
        <def>
          <p>Applicability domain</p>
        </def>
      </def-item>
      <def-item>
        <term>AI</term>
        <def>
          <p>Artificial Intelligence</p>
        </def>
      </def-item>
      <def-item>
        <term>AutoML</term>
        <def>
          <p>Automated Machine Learning</p>
        </def>
      </def-item>
      <def-item>
        <term>BBB</term>
        <def>
          <p>blood–brain barrier</p>
        </def>
      </def-item>
      <def-item>
        <term>CNS</term>
        <def>
          <p>central nervous system</p>
        </def>
      </def-item>
      <def-item>
        <term>HIA</term>
        <def>
          <p>human intestinal
absorption</p>
        </def>
      </def-item>
      <def-item>
        <term>MCC</term>
        <def>
          <p>Matthews
correlation coefficient</p>
        </def>
      </def-item>
      <def-item>
        <term>QSAR</term>
        <def>
          <p>quantitative structure–activity relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>QSPR</term>
        <def>
          <p>quantitative structure–property
relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>R<sup>2</sup></term>
        <def>
          <p>coefficient of determination</p>
        </def>
      </def-item>
      <def-item>
        <term>RMSE</term>
        <def>
          <p>root-mean-square error</p>
        </def>
      </def-item>
      <def-item>
        <term>SHAP</term>
        <def>
          <p>SHapley Additive exPlanations</p>
        </def>
      </def-item>
      <def-item>
        <term>SMILES</term>
        <def>
          <p>simplified molecular-input
line-entry system</p>
        </def>
      </def-item>
      <def-item>
        <term>TN</term>
        <def>
          <p>true negative</p>
        </def>
      </def-item>
      <def-item>
        <term>TP</term>
        <def>
          <p>true positive;</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence in drug discovery and development</article-title>. <source>Drug Discovery Today.</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Gupta</surname><given-names>R.</given-names></name>; <name><surname>Srivastava</surname><given-names>D.</given-names></name>; <name><surname>Sahu</surname><given-names>M.</given-names></name>; <name><surname>Tiwari</surname><given-names>S.</given-names></name>; <name><surname>Ambasta</surname><given-names>R. K.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name><article-title>Artificial intelligence to deep learning:
Machine intelligence approach
for drug discovery</article-title>. <source>Mol. Divers.</source><year>2021</year>, <volume>25</volume>, <fpage>1315</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1007/s11030-021-10217-3</pub-id>.<pub-id pub-id-type="pmid">33844136</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Kwon</surname><given-names>S.</given-names></name>; <name><surname>Bae</surname><given-names>H.</given-names></name>; <name><surname>Jo</surname><given-names>J.</given-names></name>; <name><surname>Yoon</surname><given-names>S.</given-names></name><article-title>Comprehensive ensemble in QSAR prediction
for drug discovery</article-title>. <source>BMC Bioinform.</source><year>2019</year>, <volume>20</volume>, <fpage>521</fpage><pub-id pub-id-type="doi">10.1186/s12859-019-3135-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Neves</surname><given-names>B. J.</given-names></name>; <name><surname>Braga</surname><given-names>R. C.</given-names></name>; <name><surname>Melo-Filho</surname><given-names>C. C.</given-names></name>; <name><surname>Moreira-Filho</surname><given-names>J. T.</given-names></name>; <name><surname>Muratov</surname><given-names>E. N.</given-names></name>; <name><surname>Andrade</surname><given-names>C. H.</given-names></name><article-title>QSAR-Based Virtual
Screening: Advances
and Applications in Drug Discovery</article-title>. <source>Front. Pharm.</source><year>2018</year>, <volume>9</volume>, <fpage>1275</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01275</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Liu</surname><given-names>R.</given-names></name>; <name><surname>So</surname><given-names>S. S.</given-names></name><article-title>Development of quantitative
structure-property relationship models
for early ADME evaluation in drug discovery. 1. Aqueous solubility</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>2001</year>, <volume>41</volume>, <fpage>1633</fpage>–<lpage>1639</lpage>. <pub-id pub-id-type="doi">10.1021/ci010289j</pub-id>.<pub-id pub-id-type="pmid">11749590</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Clark</surname><given-names>R. D.</given-names></name>; <name><surname>Daga</surname><given-names>P. R.</given-names></name><article-title>Building a Quantitative
Structure-Property Relationship
(QSPR) Model</article-title>. <source>Methods Mol. Biol.</source><year>2019</year>, <volume>1939</volume>, <fpage>139</fpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9089-4_8</pub-id>.<pub-id pub-id-type="pmid">30848460</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Sharp</surname><given-names>T.</given-names></name>; <name><surname>Barnes</surname><given-names>N. M.</given-names></name><article-title>Central 5-HT receptors
and their function; present
and future</article-title>. <source>Neuropharmacology.</source><year>2020</year>, <volume>177</volume>, <elocation-id>108155</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108155</pub-id>.<pub-id pub-id-type="pmid">32522572</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Rudnick</surname><given-names>G.</given-names></name>; <name><surname>Sandtner</surname><given-names>W.</given-names></name><article-title>Serotonin transport
in the 21st century</article-title>. <source>J. Gen Physiol.</source><year>2019</year>, <volume>151</volume> (<issue>11</issue>), <fpage>1248</fpage>–<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.201812066</pub-id>.<pub-id pub-id-type="pmid">31570504</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Newman-Tancredi</surname><given-names>A.</given-names></name>; <name><surname>Depoortère</surname><given-names>R. Y.</given-names></name>; <name><surname>Kleven</surname><given-names>M. S.</given-names></name>; <name><surname>Kołaczkowski</surname><given-names>M.</given-names></name>; <name><surname>Zimmer</surname><given-names>L.</given-names></name><article-title>Translating biased agonists from molecules to medications:
Serotonin 5-HT1A receptor functional selectivity for CNS disorders</article-title>. <source>Pharmacol Ther.</source><year>2022</year>, <volume>229</volume>, <elocation-id>107937</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107937</pub-id>.<pub-id pub-id-type="pmid">34174274</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Czub</surname><given-names>N.</given-names></name>; <name><surname>Szlęk</surname><given-names>J.</given-names></name>; <name><surname>Pacławski</surname><given-names>A.</given-names></name>; <name><surname>Klimończyk</surname><given-names>K.</given-names></name>; <name><surname>Puccetti</surname><given-names>M.</given-names></name>; <name><surname>Mendyk</surname><given-names>A.</given-names></name><article-title>Artificial
Intelligence-Based Quantitative
Structure-Property Relationship Model for Predicting Human Intestinal
Absorption of Compounds with Serotonergic Activity</article-title>. <source>Mol. Pharmaceutics</source><year>2023</year>, <volume>20</volume> (<issue>5</issue>), <fpage>2545</fpage>–<lpage>2555</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c01117</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="weblink" id="cit11">NovaDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dnastar.com/software/nova-protein-modeling/novadock/">https://www.dnastar.com/software/nova-protein-modeling/novadock/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="weblink" id="cit12">AutoDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="weblink" id="cit13">VEGA
QSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/about-vegahub/">https://www.vegahub.eu/about-vegahub/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="weblink" id="cit14">QSAR
TOOLBOX. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qsartoolbox.org/">https://qsartoolbox.org/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Ambure</surname><given-names>P.</given-names></name>; <name><surname>Halder</surname><given-names>A. K.</given-names></name>; <name><surname>Gonzalez Diaz</surname><given-names>H.</given-names></name>; <name><surname>Cordeiro</surname><given-names>M. N. D. S.</given-names></name><article-title>QSAR-Co: An
Open Source Software for Developing Robust Multitasking or Multitarget
Classification-Based QSAR Models</article-title>. <source>J. Chem. Inf
Model.</source><year>2019</year>, <volume>59</volume> (<issue>6</issue>), <fpage>2538</fpage>–<lpage>2544</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00295</pub-id>.<pub-id pub-id-type="pmid">31083984</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="weblink" id="cit16">PharmQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pharmacelera.com/pharmqsar/">https://pharmacelera.com/pharmqsar/</uri>, (accessed October 25, 2023).</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Guariento</surname><given-names>S.</given-names></name>; <name><surname>Franchini</surname><given-names>S.</given-names></name>; <name><surname>Tonelli</surname><given-names>M.</given-names></name>; et al. <article-title>Exhaustive CoMFA and
CoMSIA analyses around different chemical entities: a ligand-based
study exploring the affinity and selectivity profiles of 5-HT1A ligands</article-title>. <source>J. Enzyme Inhib Med. Chem.</source><year>2017</year>, <volume>32</volume> (<issue>1</issue>), <fpage>214</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2016.1247057</pub-id>.<pub-id pub-id-type="pmid">28114832</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18">AiQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/portfolio-item/aiqsar/">https://www.vegahub.eu/portfolio-item/aiqsar/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kausar</surname><given-names>S.</given-names></name>; <name><surname>Falcao</surname><given-names>A. O.</given-names></name><article-title>An automated framework for QSAR model building</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s13321-017-0256-5</pub-id>.<pub-id pub-id-type="pmid">29340790</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20">The GNU
General Public License, Version 3, 29 June <year>2007</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gnu.org/licenses/gpl-3.0.html">https://www.gnu.org/licenses/gpl-3.0.html</uri> (accessed July 5, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>ZINC—A free
database of commercially available
compounds for virtual screening</article-title>. <source>J. Chem. Inf.
Model.</source><year>2005</year>, <volume>45</volume>, <fpage>177</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id>.<pub-id pub-id-type="pmid">15667143</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M. P.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; et al. <article-title>ChEMBL: Towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume>, <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Cruz</surname><given-names>A.</given-names></name>; <name><surname>Ramsey</surname><given-names>S.</given-names></name>; et al. <article-title>Hidden bias in the DUD-E
dataset leads to misleading performance of deep learning in structure-based
virtual screening</article-title>. <source>PLoS One.</source><year>2019</year>, <volume>14</volume> (<issue>8</issue>), <elocation-id>e0220113</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0220113</pub-id>.<pub-id pub-id-type="pmid">31430292</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Miao</surname><given-names>R.</given-names></name>; <name><surname>Xia</surname><given-names>L. Y.</given-names></name>; <name><surname>Chen</surname><given-names>H. H.</given-names></name>; et al. <article-title>Improved Classification
of Blood-Brain-Barrier Drugs Using Deep Learning</article-title>. <source>Sci. Rep</source><year>2019</year>, <volume>9</volume>, <fpage>8802</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-44773-4</pub-id>.<pub-id pub-id-type="pmid">31217424</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="undeclared" id="cit25">Online chemical
database with modeling environment. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ochem.eu/home/show.do">https://ochem.eu/home/show.do</uri> (accessed July 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Moriwaki</surname><given-names>H.</given-names></name>; <name><surname>Tian</surname><given-names>Y. S.</given-names></name>; <name><surname>Kawashita</surname><given-names>N.</given-names></name>; <name><surname>Takagi</surname><given-names>T.</given-names></name><article-title>Mordred: A molecular
descriptor calculator</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id>.<pub-id pub-id-type="pmid">29411163</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="undeclared" id="cit27"><person-group person-group-type="allauthors"><name><surname>Plonska</surname><given-names>A.</given-names></name>; <name><surname>Plonski</surname><given-names>P.</given-names></name></person-group><article-title>MLJAR: State-of-the-Art
Automated Machine Learning Framework for Tabular Data</article-title>, version 0.10.3. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mljar/mljar-supervised">https://github.com/mljar/mljar-supervised</uri>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="weblink" id="cit28">Guidance
Document on the Validation of (Quantitative) Structure-Activity Relationship
[(Q)SAR] Models. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm">https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Pälvimäki</surname><given-names>E. P.</given-names></name>; et al. <article-title>Interactions of selective serotonin reuptake inhibitors with the
serotonin 5-HT2C receptor</article-title>. <source>Psychopharmacology</source><year>1996</year>, <volume>126</volume>, <fpage>234</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1007/BF02246453</pub-id>.<pub-id pub-id-type="pmid">8876023</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Shapiro</surname><given-names>D. A.</given-names></name>; et al. <article-title>Aripiprazole, a novel
atypical antipsychotic drug with a unique and
robust pharmacology</article-title>. <source>Neuropsychopharmacology.</source><year>2003</year>, <volume>28</volume> (<issue>8</issue>), <fpage>1400</fpage>–<lpage>1411</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300203</pub-id>.<pub-id pub-id-type="pmid">12784105</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="weblink" id="cit31">Santa
Cruz. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scbt.com/p/zolmitriptan-139264-17-8">https://www.scbt.com/p/zolmitriptan-139264-17-8</uri> (accessed November
22, 2023).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Cosi</surname><given-names>C.</given-names></name>; <name><surname>Koek</surname><given-names>W.</given-names></name><article-title>Agonist, antagonist,
and inverse agonist properties of antipsychotics
at human recombinant 5-HT<sub>1A</sub> receptors expressed in HeLa
cells</article-title>. <source>Eur. J. Pharmacol.</source><year>2001</year>, <volume>433</volume> (<issue>1</issue>), <fpage>55</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(01)01493-5</pub-id>.<pub-id pub-id-type="pmid">11755134</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Kaplan</surname><given-names>A. L.</given-names></name>; <name><surname>Confair</surname><given-names>D. N.</given-names></name>; <name><surname>Kim</surname><given-names>K.</given-names></name>; et al. <article-title>Bespoke library docking
for 5-HT2A receptor agonists with antidepressant activity</article-title>. <source>Nature.</source><year>2022</year>, <volume>610</volume>, <fpage>582</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05258-z</pub-id>.<pub-id pub-id-type="pmid">36171289</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sparaco</surname><given-names>R.</given-names></name>; <name><surname>Kędzierska</surname><given-names>E.</given-names></name>; <name><surname>Kaczor</surname><given-names>A. A.</given-names></name>; <name><surname>Bielenica</surname><given-names>A.</given-names></name>; <name><surname>Magli</surname><given-names>E.</given-names></name>; <name><surname>Severino</surname><given-names>B.</given-names></name>; <name><surname>Corvino</surname><given-names>A.</given-names></name>; <name><surname>Gibuła-Tarłowska</surname><given-names>E.</given-names></name>; <name><surname>Kotlińska</surname><given-names>J. H.</given-names></name>; <name><surname>Andreozzi</surname><given-names>G.</given-names></name>; et al. <article-title>Synthesis, Docking Studies
and Pharmacological Evaluation of Serotoninergic Ligands Containing
a 5-Norbornene-2-Carboxamide Nucleus</article-title>. <source>Molecules.</source><year>2022</year>, <volume>27</volume> (<issue>19</issue>), <fpage>6492</fpage><pub-id pub-id-type="doi">10.3390/molecules27196492</pub-id>.<pub-id pub-id-type="pmid">36235029</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Levit
Kaplan</surname><given-names>A.</given-names></name>; <name><surname>Strachan</surname><given-names>R. T.</given-names></name>; <name><surname>Braz</surname><given-names>J. M.</given-names></name>; <name><surname>Craik</surname><given-names>V.</given-names></name>; <name><surname>Slocum</surname><given-names>S.</given-names></name>; <name><surname>Mangano</surname><given-names>T.</given-names></name>; <name><surname>Amabo</surname><given-names>V.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H.</given-names></name>; <name><surname>Lak</surname><given-names>P.</given-names></name>; <name><surname>Basbaum</surname><given-names>A. I.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Structure-Based
Design of a Chemical Probe Set for the 5-HT5A Serotonin Receptor</article-title>. <source>J. Med. Chem.</source><year>2022</year>, <volume>65</volume> (<issue>5</issue>), <fpage>4201</fpage>–<lpage>4217</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02031</pub-id>.<pub-id pub-id-type="pmid">35195401</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Łażewska</surname><given-names>D.</given-names></name>; <name><surname>Więcek</surname><given-names>M.</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>Chałupnik</surname><given-names>P.</given-names></name>; <name><surname>Żesławska</surname><given-names>E.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Tarasek</surname><given-names>M.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Szymańska</surname><given-names>E.</given-names></name>; et al. <article-title>New Triazine Derivatives as Serotonin
5-HT6 Receptor Ligands</article-title>. <source>Molecules.</source><year>2023</year>, <volume>28</volume> (<issue>3</issue>), <fpage>1108</fpage><pub-id pub-id-type="doi">10.3390/molecules28031108</pub-id>.<pub-id pub-id-type="pmid">36770774</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Czarnota-Łydka</surname><given-names>K.</given-names></name>; <name><surname>Sudoł-Tałaj</surname><given-names>S.</given-names></name>; <name><surname>Kucwaj-Brysz</surname><given-names>K.</given-names></name>; <name><surname>Kurczab</surname><given-names>R.ł</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>de Candia</surname><given-names>M.</given-names></name>; <name><surname>Samarelli</surname><given-names>F.</given-names></name>; <name><surname>Altomare</surname><given-names>C. D.</given-names></name>; <name><surname>Carocci</surname><given-names>A.</given-names></name>; <name><surname>Barbarossa</surname><given-names>A.</given-names></name>; <name><surname>Zesławska</surname><given-names>E.</given-names></name>; <name><surname>Głuch-Lutwin</surname><given-names>M.</given-names></name>; <name><surname>Mordyl</surname><given-names>B.</given-names></name>; <name><surname>Kubacka</surname><given-names>M.</given-names></name>; <name><surname>Wilczynska-Zawal</surname><given-names>N.</given-names></name>; <name><surname>Jastrzebska-Wiesek</surname><given-names>M.</given-names></name>; <name><surname>Partyka</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>N.</given-names></name>; <name><surname>Wiecek</surname><given-names>M.łg.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Wesołowska</surname><given-names>A.</given-names></name>; <name><surname>Carrieri</surname><given-names>A.</given-names></name>; <name><surname>Handzlik</surname><given-names>J.</given-names></name><article-title>Synthesis,
computational and experimental pharmacological studies for (thio)ether-triazine
5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent
intrinsic activity in search for new class of drugs against Alzheimer’s
disease</article-title>. <source>Eur. J. Med. Chem.</source><year>2023</year>, <volume>259</volume>, <fpage>115695</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115695</pub-id>.<pub-id pub-id-type="pmid">37567058</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Penjisevic</surname><given-names>J. Z.</given-names></name>; <name><surname>Sukalovic</surname><given-names>V. B.</given-names></name>; <name><surname>Dukic-Stefanovic</surname><given-names>S.</given-names></name>; <name><surname>Deuther-Conrad</surname><given-names>W.</given-names></name>; <name><surname>Andric</surname><given-names>D. B.</given-names></name>; <name><surname>Kostic-Rajacic</surname><given-names>S.đa.
V.</given-names></name><article-title>Synthesis of novel 5-HT1A
arylpiperazine ligands: Binding data and computer-aided analysis of
pharmacological potency</article-title>. <source>Arab. J. Chem.</source><year>2023</year>, <volume>16</volume>, <fpage>104636</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2023.104636</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><person-group person-group-type="allauthors"><name><surname>Shapley</surname><given-names>L. S.</given-names></name></person-group><article-title>A Value for
N-Person Games</article-title>. <publisher-name>RAND Corporation</publisher-name>: <publisher-loc>Santa Monica, CA</publisher-loc>, <year>1952</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rand.org/pubs/papers/P295.html">https://www.rand.org/pubs/papers/P295.html</uri>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="undeclared" id="cit40"><person-group><name><surname>Lundberg</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>S. I.</given-names></name></person-group><article-title>A Unified Approach to Interpreting
Model Predictions</article-title>. <source>ArXiv Preprint</source>, arXiv:1705.07874, <year>2017</year>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="undeclared" id="cit41"><person-group person-group-type="allauthors"><name><surname>Szlęk</surname><given-names>J.</given-names></name></person-group><article-title>Model
Interpretation</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/jszlek/MODEL_INTERPRETATION">https://github.com/jszlek/MODEL_INTERPRETATION</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="weblink" id="cit42">Steamlit:
a faster way to build and share data apps. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://streamlit.io/">https://streamlit.io/</uri> (accessed
June 2, 2023).</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Sivandzade</surname><given-names>F.</given-names></name>; <name><surname>Cucullo</surname><given-names>L.</given-names></name><article-title>In-vitro blood-brain
barrier modeling: A review of
modern and fast-advancing technologies</article-title>. <source>J. Cereb
Blood Flow Metab.</source><year>2018</year>, <volume>38</volume> (<issue>10</issue>), <fpage>1667</fpage>–<lpage>1681</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X18788769</pub-id>.<pub-id pub-id-type="pmid">30058456</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="weblink" id="cit44">Canva. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/">https://www.canva.com/</uri> (accessed
10 June 2023).</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="undeclared" id="cit45a">Streamlit
ketcher. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io">https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io</uri> (accessed July 15, 2023).</mixed-citation>
      <mixed-citation publication-type="journal" id="cit45b"><name><surname>Abuhelwa</surname><given-names>A. Y.</given-names></name>; <name><surname>Williams</surname><given-names>D. B.</given-names></name>; <name><surname>Upton</surname><given-names>R. N.</given-names></name>; <name><surname>Foster</surname><given-names>D. J.</given-names></name><article-title>Food, gastrointestinal pH, and models of oral drug
absorption</article-title>. <source>Eur. J. Pharm. Biopharm.</source><year>2017</year>, <volume>112</volume>, <fpage>234</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2016.11.034</pub-id>.<pub-id pub-id-type="pmid">27914234</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11005036</article-id>
    <article-id pub-id-type="pmid">38289046</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.3c01517</article-id>
    <article-categories>
      <subj-group>
        <subject>Application Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SerotoninAI: Serotonergic
System Focused, Artificial
Intelligence-Based Application for Drug Discovery</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6660-4446</contrib-id>
        <name>
          <surname>Łapińska</surname>
          <given-names>Natalia</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2801-6197</contrib-id>
        <name>
          <surname>Pacławski</surname>
          <given-names>Adam</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1537-9650</contrib-id>
        <name>
          <surname>Szlęk</surname>
          <given-names>Jakub</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4394-9115</contrib-id>
        <name>
          <surname>Mendyk</surname>
          <given-names>Aleksander</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Pharmaceutical Technology and Biopharmaceutics, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
      <aff id="aff2"><label>‡</label>Doctoral
School of Medicinal and Health Sciences, <institution>Jagiellonian University Medical College</institution>, 30-688 Kraków, <country>Poland</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>j.szlek@uj.edu.pl</email>. Tel.: <phone>+48-(12)-6205604</phone>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>30</day>
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>08</day>
      <month>04</month>
      <year>2024</year>
    </pub-date>
    <volume>64</volume>
    <issue>7</issue>
    <issue-title>Machine
Learning in Bio-cheminformatics</issue-title>
    <fpage>2150</fpage>
    <lpage>2157</lpage>
    <history>
      <date date-type="received">
        <day>21</day>
        <month>09</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>01</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>02</day>
        <month>01</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2024 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2024</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0004" id="ab-tgr1"/>
      </p>
      <p>SerotoninAI is an innovative web application for scientific
purposes
focused on the serotonergic system. By leveraging SerotoninAI, researchers
can assess the affinity (pKi value) of a molecule to all main serotonin
receptors and serotonin transporters based on molecule structure introduced
as SMILES. Additionally, the application provides essential insights
into critical attributes of potential drugs such as blood–brain
barrier penetration and human intestinal absorption. The complexity
of the serotonergic system demands advanced tools for accurate predictions,
which is a fundamental requirement in drug development. SerotoninAI
addresses this need by providing an intuitive user interface that
generates predictions of pKi values for the main serotonergic targets.
The application is freely available on the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://serotoninai.streamlit.app/">https://serotoninai.streamlit.app/</uri>, implemented in Streamlit with all major web browsers supported.
Currently, to the best of our knowledge, there is no tool that allows
users to access affinity predictions for serotonergic targets without
registration or financial obligations. SerotoninAI significantly increases
the scope of drug development activities worldwide. The source code
of the application is available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Uniwersytet Jagiellonski Collegium Medicum</institution>
            <institution-id institution-id-type="doi">10.13039/100009045</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>7N42/DBS/000205</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci3c01517</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>The rise and development
of artificial intelligence (AI) tools
have a revolutionary impact on many areas of science and industry.
In the field of drug design, AI is showing the potential to change
traditional approaches, enabling faster and more efficient discovery
and development of new therapeutic agents.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> One
of the benefits of AI is the development of advanced QSAR (quantitative
structure–activity relationship) and QSPR (quantitative structure–property
relationship) models. Their ability to screen new active compounds,
possible side effects, bioavailability and other properties can speed
up and increase cost effectiveness both of the drug discovery and
development phases.<sup><xref ref-type="bibr" rid="ref3">3</xref>−<xref ref-type="bibr" rid="ref6">6</xref></sup></p>
    <p>Our work focuses on serotonin receptors and transporters.
Selected
biological targets are important for many drugs that impact the central
nervous system (CNS). Substances that affect the serotonergic system
are used to treat mood, migraine, regulate sleep, and treat neurotic
disorders or eating disorders. Furthermore, recent studies show that
they can improve cognitive function. Preliminary studies also show
that they may represent an even broader spectrum of therapeutic applications
than CNS activity. For example, the serotonin 5-HT2C receptor has
a role in impulse control, and the 5-HT3 receptor plays a role in
controlling nausea and vomiting.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref></sup></p>
    <p>SerotoninAI is an application
focused on compounds with a serotonergic
activity. It allows predictions of affinity for various 5-HT receptors
as well as the serotonin transporter. The affinity for a selected
biological target ensures a potential application of a molecule as
a future drug and allows us to anticipate possible side effects. Moreover,
SerotoninAI predicts human intestinal absorption (HIA) and blood–brain
barrier (BBB) penetration of the given chemical structure. For the
molecule, a confirmed BBB penetration is a crucial property for drugs
acting on the central nervous system, whereas extensive HIA ensures
feasibility of the oral administration route, the most preferred and
acceptable one in the therapy. The artificial intelligence (AI)-based
system for HIA has been developed on data sets with serotonergic ligands,
which limits its application to these molecules only.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></p>
    <p>There are a number of ready-to-use programs for assessing
protein–molecule
interactions which the main task is to dock molecules in the corresponding
protein, such as NovaDock<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> and AutoDock.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> On the other hand, VEGA QSAR<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and QSAR TOOLBOX<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> do not provide
predictions of affinity for selected receptors. Their application
focuses on physical and chemical properties and also ADME-TOX properties.
In contrast, typical QSAR models are provided by applications such
as QSAR-Co<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and PharmQSAR.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> In the case of QSAR-Co, the prediction capabilities
are limited to classification models. Moreover, to obtain predictions,
the user needs to download and run the tool’s own machine,
which might introduce some difficulties related to OS/machine specification.
Moreover, the authors of the application do not provide ready-to-use
models related to the serotonin system. PharmQSAR allows the creation
of statistical models using techniques CoMFA (Comparative Molecular
Field Analysis) and CoMSIA (Comparative Molecular Similarity Indices
Analysis)<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> and also does not provide models
for serotonin receptors and transporters. In the aforementioned applications
for QSAR models, whether ready-made or with the ability to create
them, registration is required, which greatly limits the use of such
an application. Provided preliminary limitations for users prevent
us from directly comparing the presented systems with our models.</p>
    <p>The only tool available without registration that provides QSAR
models is aiQSAR.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> In order to use the
ready-made models, we need to download the applications to our own
machine. However, among the 38 biological targets, there is none related
to the serotonin system. A publication describing QSAR models for
serotonin receptors is the work of Kausar et al.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> They describe the results for most serotonin receptors,
but we have no way of comparing the results because databases are
not available (no information about training and test set beyond the
number of molecules). When considering the available tools, we decided
to create SerotoninAI as the missing piece to accelerate the drug
discovery process.</p>
    <p>SerotoninAI as a web-based app allows users
to easily obtain predictions
for chosen molecules without the need for installing any tools on
their own computers, as well as without any programming skills. To
the best of our knowledge, SerotoninAI is the first affinity prediction
tool for serotonin targets without mandatory registration of a user.
Moreover, the only information needed from the user side is SMILES
(Simplified Molecular Input Line Entry Specification) of a molecule.
It is worth mentioning that the application is distributed under the
GNU General Public License version 3<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> and
the source code is provided on the GitHub platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/SerotoninAI_streamlit">https://github.com/nczub/SerotoninAI_streamlit</uri>).</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Results and Discussion</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Databases</title>
      <p>The application uses QSAR
models developed on data extracted from two leading databases, namely,
ZINC and ChEMBL (data extracted in December 2022).<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> Data were acquired for each target involving serotonergic activity,
that is, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4,
5-HT5A, 5-HT6, 5-HT7, and the serotonin transporter SERT. Despite
the presence of ligands for 5-HT1E and 5-HT1F as well as 5-HT5B receptors
these databases were not used to create models due to their small
size (&lt;500 molecules) resulting in the limited applicability domain.
Our approach was to provide models based only on the experimentally
validated data; therefore, no decoys were used in any of the training
or testing data sets.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>
      <p>The dependent
variable was the value of ligand affinity presented as the negative
logarithm of the inhibition constant, the pKi value. In the data preparation
part, duplicates were first removed from the ZINC and ChEMBL databases
separately, and invalid SMILES were removed. No other specific structure
curation was employed. The two databases were then merged, and some
molecules were present in both databases. Molecule pairs with a pKi
difference greater than 0.1 were removed from the database. In the
group of molecule pairs with a pKi difference equal to or less than
0.1, the ZINC molecule was selected as the reference substance. The
databases were randomly divided into training and test sets at a ratio
of 80:20. The former part of the data (80%) was used to develop QSAR
models according to the 10-fold cross validation scheme, and the latter
(20%) was used as an external test set. <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref> shows histograms of pKi values for each
biological target according to the training and test set.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Histograms
of the pKi values: (A) 5-HT1A serotonin receptor. (B)
5-HT1B serotonin receptor. (C) 5-HT1D serotonin receptor. (D) 5-HT2A
serotonin receptor. (E) 5-HT2B serotonin receptor. (F) 5-HT2C serotonin
receptor. (G) 5-HT3 serotonin receptor. (H) 5-HT4 serotonin receptor.
(I) 5-HT5A serotonin receptor. (J) 5-HT6 serotonin receptor. (K) 5-HT7
serotonin receptor. (L) Serotonin transporter SERT.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0001" id="gr1" position="float"/>
      </fig>
      <p>The database for predicting HIA was described in
our previous work;<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> the source of the
data was literature data and
the ChEMBL database.</p>
      <p>QSPR classification model of BBB permeability
was based on the
database collected from the work of Miao et al.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> (data set 1 and data set 2) and enriched by us with data
from OCHEM database<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> (data extracted in
July 2023). It resulted in 2853 molecules in the training set. An
independent test set from the article by Miao et al. remained in the
test set of our experiment (161 molecules) in order to better compare
our developed QSPR model.</p>
      <p>All data are available in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">Supporting Information</ext-link> as a single database.zip
file containing separate training/test
csv files for each respective biological target.</p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Molecular Representation</title>
      <p>Mordred
descriptors were used as a molecular representation of chemical structures.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Mordred effectiveness in this field and suitability
for interpretation has been tested in our previous work.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> QSAR and QSPR models were created based on two-dimensional
descriptors to prevent the risk of variability in three-dimensional
descriptors due to nonconvergent molecules’ optimization. Based
on SMILES, SerotoninAI automatically creates the molecular descriptors
required by the models.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>QSAR and QSPR Models</title>
      <p>Modeling was
performed with the mljar-supervised tool, which belongs to the field
of Automated Machine Learning (AutoML).<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> In the case of receptors, serotonin transporter and BBB permeability
models were de novo created for the purpose of the presented application.
On the other hand, for human intestinal absorption, the AI-based system
has already been published<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and has been
implemented in this application without any further modifications.</p>
      <p>QSAR regression models were created according to the 10-fold cross-validation
scheme (10-CV) on 80% of the curated databases. For each target, about
2000 models were developed. We used root-mean-square error (RMSE)
and coefficient of determination (<italic>R</italic><sup>2</sup>)
values to evaluate and select the best models (<xref rid="eq1" ref-type="disp-formula">eqs <xref rid="eq1" ref-type="disp-formula">1</xref></xref> and <xref rid="eq2" ref-type="disp-formula">2</xref>), in accordance
with the guidelines of the Organization for Economic Co-operation
and Development’s QSAR models.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The results were analyzed for the training set (10-CV) and the separate
test set (20%). In <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, we show the detailed results for each QSAR model.<disp-formula id="eq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m001" position="anchor"/><label>1</label></disp-formula>where RMSE = root-mean-square
error, obs<sub><italic>i</italic></sub> and pred<sub><italic>i</italic></sub> = observed and predicted values, <italic>i</italic> = data
record number, and <italic>n</italic> = total number of records.<disp-formula id="eq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m002" position="anchor"/><label>2</label></disp-formula>where <italic>R</italic><sup>2</sup> = the coefficient of determination, SS<sub>res</sub> = the
sum of squares of the residual errors, S<italic>S</italic><sub>tot</sub> = the total sum of the errors, obs<sub><italic>i</italic></sub> and
pred<sub><italic>i</italic></sub> = observed and predicted values,
and obs = arithmetical mean of observed values.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Number of Ligands for Each Target,
Number of Descriptors Used for QSAR Models after Removing Constant
and Highly Correlated Variables, Results for Training Set and Test
Set, and Type of Each Model of QSAR Models</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Number of ligands</th>
              <th style="border:none;" align="center">Number of descriptors</th>
              <th style="border:none;" align="center">RMSE 10-CV</th>
              <th style="border:none;" align="center">R<sup>2</sup> 10-CV</th>
              <th style="border:none;" align="center">RMSE test</th>
              <th style="border:none;" align="center">R<sup>2</sup> test</th>
              <th style="border:none;" align="center">Model type</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">10,175</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.555</td>
              <td style="border:none;" align="center">0.733</td>
              <td style="border:none;" align="center">0.629</td>
              <td style="border:none;" align="center">0.660</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">1833</td>
              <td style="border:none;" align="center">710</td>
              <td style="border:none;" align="center">0.627</td>
              <td style="border:none;" align="center">0.731</td>
              <td style="border:none;" align="center">0.558</td>
              <td style="border:none;" align="center">0.805</td>
              <td style="border:none;" align="center">Ensemble model (5x Xgboost, 4x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">2072</td>
              <td style="border:none;" align="center">739</td>
              <td style="border:none;" align="center">0.566</td>
              <td style="border:none;" align="center">0.836</td>
              <td style="border:none;" align="center">0.536</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">Ensemble model (5x
Xgboost, 4x LightGBM, 2x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6926</td>
              <td style="border:none;" align="center">703</td>
              <td style="border:none;" align="center">0.582</td>
              <td style="border:none;" align="center">0.769</td>
              <td style="border:none;" align="center">0.567</td>
              <td style="border:none;" align="center">0.764</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">2821</td>
              <td style="border:none;" align="center">723</td>
              <td style="border:none;" align="center">0.561</td>
              <td style="border:none;" align="center">0.674</td>
              <td style="border:none;" align="center">0.607</td>
              <td style="border:none;" align="center">0.608</td>
              <td style="border:none;" align="center">Ensemble model (6x Xgboost, 2x LightGBM, 5x CatBoost)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">5097</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">0.625</td>
              <td style="border:none;" align="center">0.673</td>
              <td style="border:none;" align="center">0.603</td>
              <td style="border:none;" align="center">0.685</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">562</td>
              <td style="border:none;" align="center">665</td>
              <td style="border:none;" align="center">0.837</td>
              <td style="border:none;" align="center">0.672</td>
              <td style="border:none;" align="center">0.867</td>
              <td style="border:none;" align="center">0.680</td>
              <td style="border:none;" align="center">Ensemble model (2x Xgboost, 3x CatBoost, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT4</td>
              <td style="border:none;" align="center">949</td>
              <td style="border:none;" align="center">516</td>
              <td style="border:none;" align="center">0.682</td>
              <td style="border:none;" align="center">0.753</td>
              <td style="border:none;" align="center">0.690</td>
              <td style="border:none;" align="center">0.697</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">720</td>
              <td style="border:none;" align="center">704</td>
              <td style="border:none;" align="center">0.575</td>
              <td style="border:none;" align="center">0.797</td>
              <td style="border:none;" align="center">0.568</td>
              <td style="border:none;" align="center">0.761</td>
              <td style="border:none;" align="center">Ensemble model (3x Xgboost, 3x CatBoost,
1x ExtraTrees, 1x LightGBM)</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">5925</td>
              <td style="border:none;" align="center">688</td>
              <td style="border:none;" align="center">0.579</td>
              <td style="border:none;" align="center">0.777</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.749</td>
              <td style="border:none;" align="center">Xgboost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">4411</td>
              <td style="border:none;" align="center">727</td>
              <td style="border:none;" align="center">0.624</td>
              <td style="border:none;" align="center">0.684</td>
              <td style="border:none;" align="center">0.601</td>
              <td style="border:none;" align="center">0.728</td>
              <td style="border:none;" align="center">CatBoost</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8091</td>
              <td style="border:none;" align="center">541</td>
              <td style="border:none;" align="center">0.490</td>
              <td style="border:none;" align="center">0.851</td>
              <td style="border:none;" align="center">0.492</td>
              <td style="border:none;" align="center">0.858</td>
              <td style="border:none;" align="center">LightGBM</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>In <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>, we have
presented examples of drugs available on the market along with their
affinities from literature sources and pKi values predicted by the
SerotoninAI.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>SerotoninAI’s Predictions and
Literature Values of pKi for Drug Examples Related to Serotonergic
System</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">Drug</th>
              <th style="border:none;" align="center">Target</th>
              <th style="border:none;" align="center">Experimental/Literature pKi value</th>
              <th style="border:none;" align="center">SerotoninAI
prediction</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Fluoxetine<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></td>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">6.150</td>
              <td style="border:none;" align="center">6.631</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.371</td>
              <td style="border:none;" align="center">6.308</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">8.708</td>
              <td style="border:none;" align="center">8.013</td>
            </tr>
            <tr>
              <td rowspan="11" style="border:none;" align="center">Aripiprazole<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">8.252</td>
              <td style="border:none;" align="center">7.527</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">6.081</td>
              <td style="border:none;" align="center">5.913</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">7.167</td>
              <td style="border:none;" align="center">6.753</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A</td>
              <td style="border:none;" align="center">8.060</td>
              <td style="border:none;" align="center">8.366</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B</td>
              <td style="border:none;" align="center">9.444</td>
              <td style="border:none;" align="center">7.982</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C</td>
              <td style="border:none;" align="center">7.119</td>
              <td style="border:none;" align="center">7.195</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT3</td>
              <td style="border:none;" align="center">6.202</td>
              <td style="border:none;" align="center">6.160</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A</td>
              <td style="border:none;" align="center">5.907</td>
              <td style="border:none;" align="center">5.890</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6</td>
              <td style="border:none;" align="center">6.244</td>
              <td style="border:none;" align="center">6.716</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7</td>
              <td style="border:none;" align="center">7.987</td>
              <td style="border:none;" align="center">7.570</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">SERT</td>
              <td style="border:none;" align="center">5.967</td>
              <td style="border:none;" align="center">6.646</td>
            </tr>
            <tr>
              <td rowspan="3" style="border:none;" align="center">Zolmitriptan<sup><xref ref-type="bibr" rid="ref31">31</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">7.105</td>
              <td style="border:none;" align="center">6.562</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B</td>
              <td style="border:none;" align="center">8.377</td>
              <td style="border:none;" align="center">8.089</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1D</td>
              <td style="border:none;" align="center">9.199</td>
              <td style="border:none;" align="center">8.733</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Clozapine<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></td>
              <td style="border:none;" align="center">5-HT1A</td>
              <td style="border:none;" align="center">6.990</td>
              <td style="border:none;" align="center">6.357</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The examples presented above are also included in
curated databases
prepared to create QSAR models, which do not constitute the usefulness
of such a model for unseen examples of molecules. Therefore, we decided
to test the created models on the latest available data. For this
purpose, we reviewed the literature from 2022, when the first databases
were created. New experimental data were available for seven biological
targets (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and
5-HT7).<sup><xref ref-type="bibr" rid="ref33">33</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> In <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>, we present
summary results for each receptor and the sum of predictions, using
SerotoninAI, located in four categories: when the prediction difference
was less than 0.5, greater than or equal to 0.5 and less than 1.0,
the third group being prediction differences equal to or greater than
1.0 and less than 2.0, and the last group indicating a very large
prediction difference, a value equal to or greater than 2.0. All predictions
are available in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">Supporting Information S1</ext-link>. The worst predictions are seen for the 5-HT5A receptor. In our
opinion, this is due to too little differentiated data. Of the seven
targets for which external data were available, the database for the
5-HT5A receptor was the smallest (720 molecules).</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <title>Summary of pKi Pedictions by SerotoninAI
for New Experimental Data Available in the Literature in the Years
2022–2023</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th colspan="4" align="center">Differences
of literature data and SerotoninAI predictions of pKi<hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">receptor</th>
              <th style="border:none;" align="center">&lt;0.5</th>
              <th style="border:none;" align="center">≥0.5 and &lt;1.0</th>
              <th style="border:none;" align="center">≥1.0 and &lt;2.0</th>
              <th style="border:none;" align="center">≥2.0</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">5-HT1A<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">2</td>
              <td style="border:none;" align="center">13</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT1B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2A<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">31</td>
              <td style="border:none;" align="center">15</td>
              <td style="border:none;" align="center">6</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2B<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></td>
              <td style="border:none;" align="center">3</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT2C<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">4</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT5A<sup><xref ref-type="bibr" rid="ref35">35</xref></sup></td>
              <td style="border:none;" align="center">5</td>
              <td style="border:none;" align="center">–</td>
              <td style="border:none;" align="center">1</td>
              <td style="border:none;" align="center">6</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT6<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">24</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">8</td>
              <td style="border:none;" align="center">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">5-HT7<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></td>
              <td style="border:none;" align="center">23</td>
              <td style="border:none;" align="center">11</td>
              <td style="border:none;" align="center">10</td>
              <td style="border:none;" align="center">–</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">total</td>
              <td style="border:none;" align="center">102</td>
              <td style="border:none;" align="center">44</td>
              <td style="border:none;" align="center">38</td>
              <td style="border:none;" align="center">8</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The QSPR model for BBB penetration was a binary classification
model (1, molecule penetrates to brain; 0, no penetration). It was
also created according to 10-CV. To evaluate the model, classification
metrics like accuracy, precision, recall, F1 score, and Matthews correlation
coefficient (MCC) were used (<xref rid="eq3" ref-type="disp-formula">eqs <xref rid="eq3" ref-type="disp-formula">3</xref></xref>–<xref rid="eq7" ref-type="disp-formula">7</xref>). These results and confusion
matrices for the training and test set are shown in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref> and <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>. We compared our results on the test set
with the recent article on BBB penetration,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and our model resulted in more accurate predictions. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">Supporting Information S2</ext-link> provides a detailed
description of these results.<disp-formula id="eq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m003" position="anchor"/><label>3</label></disp-formula><disp-formula id="eq4"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m004" position="anchor"/><label>4</label></disp-formula><disp-formula id="eq5"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m005" position="anchor"/><label>5</label></disp-formula><disp-formula id="eq6"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m006" position="anchor"/><label>6</label></disp-formula>where TP = true positive, TN = true negative,
FP = false positive, and FN = false negative.<disp-formula id="eq7"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_m007" position="anchor"/><label>7</label></disp-formula></p>
      <table-wrap id="tbl4" position="float">
        <label>Table 4</label>
        <caption>
          <title>Summary of Classification Metrics
for Training and Test Set for the Blood–Brain Barrier Penetration
Model</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="center"/>
            <col align="center"/>
            <col align="center"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th style="border:none;" align="center">Training set (10-CV)</th>
              <th style="border:none;" align="center">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="center">Accuracy</td>
              <td style="border:none;" align="center">0.94</td>
              <td style="border:none;" align="center">0.87</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Precision</td>
              <td style="border:none;" align="center">1.00</td>
              <td style="border:none;" align="center">0.80</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Recall</td>
              <td style="border:none;" align="center">0.91</td>
              <td style="border:none;" align="center">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">F1 score</td>
              <td style="border:none;" align="center">0.96</td>
              <td style="border:none;" align="center">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Matthews correlation coefficient</td>
              <td style="border:none;" align="center">0.88</td>
              <td style="border:none;" align="center">0.76</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Number
of compounds</td>
              <td style="border:none;" align="center">2853</td>
              <td style="border:none;" align="center">161</td>
            </tr>
            <tr>
              <td style="border:none;" align="center">Type of model</td>
              <td colspan="2" align="center">Ensemble model (5x Xgboost, 7x NeuralNetwork, 2x LightGBM)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Confusion matrices for training and test sets: blood–-brain
barrier QSPR model.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0002" id="gr2" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Applicability Domain</title>
      <p>The major challenge
that researchers face in developing QSAR or QSPR models is the scarcity
of data. Based on the available data, the model predicts correctly
within the relevant ranges of descriptors. For these reasons, SerotoninAI
with each prediction provides information on whether the studied compound
is within the applicability domain (AD) or not. Naturally, within-AD
predictions are characterized with higher accuracy even though the
compound is unknown to the system, namely, beyond the training data.</p>
      <p>The AD was obtained based on the 10 most important descriptors
for each model. The importance ranking of the descriptors was obtained
using SHAP analysis. SHAP (Shapley Additive Explanations) is a method
used to explain complex AI/ML models. It is based on a concept called
the Shapley value, introduced by Lloyd Shapley in 1952.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Shapley, who was distinguished for his input
in game theory by the Nobel Memorial Prize in Economic Sciences in
2012, focused on how to fairly divide rewards from the game among
cooperating players. The solution for the analyzed problem should
allow for splitting the reward of the team among all players in a
proportional way to its contribution to the result and at the same
time fulfill criteria of efficiency, additivity, symmetry, and null
player presence detection. The unique solution for that problem is
the Shapley value which divides the reward based on each player’s
marginal contribution, ensuring fairness. In the realm of predictive
modeling, this framework can be adapted to assess the incremental
contribution of each input variable of the model to the predicted
outcome.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> In this study, we employed SHAP
analysis to examine the overarching influence of each variable, considering
both the magnitude and the direction (high or low values of the variable)
of its impact on the final prediction. This analysis was conducted
in Python environment, leveraging a framework developed by Szlęk,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> further augmented with a wrapper for the mljar
package. Summary plots of SHAP analysis for each obtained model are
presented in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">Supporting Information S3</ext-link>,
except for the HIA model, where the entire analysis was described
in previous article.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The values of these
descriptors in the training set were transformed via Min–Max
normalization. A compound is under AD if seven descriptors are in
the range between minimum and maximum values of the training set. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref> presents examples
of compounds within and outside the applicability domain.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>A comparison
of the molecule’s applicability domains. (Left)
A molecule within the applicability domain. (Right) A molecule out
of the applicability domain. The gray area indicates the application
domain.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_0003" id="gr3" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.5">
      <label>2.5</label>
      <title>Application Development</title>
      <p>SerotoninAI
was developed using Streamlit, an open-source Python library that
simplifies the process of developing web applications. It enables
developers to create interactive and user-friendly web applications
using Python scripts.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> Our app includes
pharmacological descriptions for each biological target and a medical
and biopharmaceutical introduction to intestinal permeability and
blood–brain barrier based on literature data.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> This enables scientists to better
understand the mechanisms of action of these receptors and identify
potential targets for new drugs. This knowledge can accelerate the
drug discovery process, enabling scientists to design compounds with
the desired pharmacological properties. The graphics page was enhanced
with images created using Canva software.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup></p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Implementation</title>
    <p>SerotoninAI operates
in several modes. The user can obtain predictions
for the target’s affinity or class of HIA and BBB, either for
a single compound or based on a collection of molecules represented
by a CSV file, the so-called batch mode. However, due to limited resources
provided by the Streamlit server, we encourage users to run batch
mode locally on their own machines. From the user’s perspective,
the model makes predictions based on SMILES, imported directly from
the DrugBank/ChEMBL/ZINC without a specific structure curation. In
the case of a CSV file, compounds should be represented in a column
named “smiles”. There is also the possibility to draw
molecules and obtain particular SMILES.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup></p>
    <p>Another feature of the application is to obtain a prediction
for
one biological target only, multiple user-selected targets, or all
of them at once. Depending on the research needs, scientists may choose
which serotonin receptors are relevant. This mode works with only
a CSV file. It is worth remembering that with more molecules and more
targets under study, the prediction time increases. The result of
the predictions for multiple molecules is a downloadable file with
ready-made predictions. As in the case of individual predictions for
a single target, information about the applicability domain appears.
In the case of batch mode, it takes the values “True”
or “False”, where “True” means that the
tested compound is in the AD defined in <xref rid="sec2.4" ref-type="other">section <xref rid="sec2.4" ref-type="other">2.4</xref></xref>.</p>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusion</title>
    <p>The developed SerotoninAI
application is publicly available AI-based
software for obtaining affinity and permeability predictions for the
intestinal wall and blood–brain barrier. The use of such predictions
for serotonin receptors and transporters can significantly accelerate
the time to find new compounds with potential pharmacological activity,
mainly in the field of central nervous system diseases. This application,
governed by the GNU General Public License version 3,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> comes with no liability from the authors for the obtained
results. The published version of the app is not password protected;
neither is the data privacy ensured. For the latter, the user must
download the source code and install the app in the controlled environment.</p>
    <p>Limitations due to the small amount of data to create models for
several serotonin receptors (5-HT1E, 5-HT1E, and 5-HT5B) will be overcome
when more data about ligands for these receptors are published. SerotoninAI
will be updated on an ongoing basis for at least 2 years when larger
databases become available and/or better predictive models can be
obtained. Due to limited resources available to streamlit applications,
batch mode computations should be run locally.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes-2">
    <title>Data Availability Statement</title>
    <p>The data underlying
this study are available in the published article and its <xref rid="notes-1" ref-type="notes">Supporting Information</xref>, except the data used
for developing HIA model, which are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/nczub/HIA_5-HT">https://github.com/nczub/HIA_5-HT</uri>.</p>
  </notes>
  <notes id="notes-1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting
Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.3c01517</ext-link>.<list id="silist" list-type="simple"><list-item><p>Supporting Information S1, Table 1: prediction results
of external data of ligands for seven targets of serotonin system
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_001.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S2, Table 2: prediction results
of 161 compounds, test set of blood–brain barrier model (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Supporting
Information S3, Figure: Summary plot of SHAP
analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_003.pdf">PDF</ext-link>)</p></list-item><list-item><p>Databases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.3c01517/suppl_file/ci3c01517_si_004.zip">ZIP</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_001.xlsx">
        <caption>
          <p>ci3c01517_si_001.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_002.xlsx">
        <caption>
          <p>ci3c01517_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_003.pdf">
        <caption>
          <p>ci3c01517_si_003.pdf</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile4">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci3c01517_si_004.zip">
        <caption>
          <p>ci3c01517_si_004.zip</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d14e1139-autogenerated">
    <p>The authors declare
no
competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This research/study was carried out with
the use of research
infrastructure cofinanced by the Smart Growth Operational Programme
POIR 4.2 project no. POIR.04.02.00-00-D023/20. Research was partially
supported by Jagiellonian University Medical College in Kraków,
Grant Number 7N42/DBS/000205. Equipment was also cofinanced by the
qLIFE Priority Research Area under the program “Excellence
Initiative—Research University” at Jagiellonian University.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>10-CV</term>
        <def>
          <p>10-fold
cross-validation</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT</term>
        <def>
          <p>5-hydroxytryptamine,
serotonin</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1A</sub></term>
        <def>
          <p>serotonin 1A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1B</sub></term>
        <def>
          <p>serotonin 1B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1D</sub></term>
        <def>
          <p>serotonin
1D receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1E</sub></term>
        <def>
          <p>serotonin 1E receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>1F</sub></term>
        <def>
          <p>serotonin 1F receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2A</sub></term>
        <def>
          <p>serotonin
2A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2B</sub></term>
        <def>
          <p>serotonin 2B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>2C</sub></term>
        <def>
          <p>serotonin 2C receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>3</sub></term>
        <def>
          <p>serotonin
3 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>4</sub></term>
        <def>
          <p>serotonin 4 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5A</sub></term>
        <def>
          <p>serotonin 5A receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>5B</sub></term>
        <def>
          <p>serotonin 5B receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>6</sub></term>
        <def>
          <p>serotonin
6 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>5-HT<sub>7</sub></term>
        <def>
          <p>serotonin 7 receptor</p>
        </def>
      </def-item>
      <def-item>
        <term>AD</term>
        <def>
          <p>Applicability domain</p>
        </def>
      </def-item>
      <def-item>
        <term>AI</term>
        <def>
          <p>Artificial Intelligence</p>
        </def>
      </def-item>
      <def-item>
        <term>AutoML</term>
        <def>
          <p>Automated Machine Learning</p>
        </def>
      </def-item>
      <def-item>
        <term>BBB</term>
        <def>
          <p>blood–brain barrier</p>
        </def>
      </def-item>
      <def-item>
        <term>CNS</term>
        <def>
          <p>central nervous system</p>
        </def>
      </def-item>
      <def-item>
        <term>HIA</term>
        <def>
          <p>human intestinal
absorption</p>
        </def>
      </def-item>
      <def-item>
        <term>MCC</term>
        <def>
          <p>Matthews
correlation coefficient</p>
        </def>
      </def-item>
      <def-item>
        <term>QSAR</term>
        <def>
          <p>quantitative structure–activity relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>QSPR</term>
        <def>
          <p>quantitative structure–property
relationship</p>
        </def>
      </def-item>
      <def-item>
        <term>R<sup>2</sup></term>
        <def>
          <p>coefficient of determination</p>
        </def>
      </def-item>
      <def-item>
        <term>RMSE</term>
        <def>
          <p>root-mean-square error</p>
        </def>
      </def-item>
      <def-item>
        <term>SHAP</term>
        <def>
          <p>SHapley Additive exPlanations</p>
        </def>
      </def-item>
      <def-item>
        <term>SMILES</term>
        <def>
          <p>simplified molecular-input
line-entry system</p>
        </def>
      </def-item>
      <def-item>
        <term>TN</term>
        <def>
          <p>true negative</p>
        </def>
      </def-item>
      <def-item>
        <term>TP</term>
        <def>
          <p>true positive;</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Paul</surname><given-names>D.</given-names></name>; <name><surname>Sanap</surname><given-names>G.</given-names></name>; <name><surname>Shenoy</surname><given-names>S.</given-names></name>; <name><surname>Kalyane</surname><given-names>D.</given-names></name>; <name><surname>Kalia</surname><given-names>K.</given-names></name>; <name><surname>Tekade</surname><given-names>R. K.</given-names></name><article-title>Artificial intelligence in drug discovery and development</article-title>. <source>Drug Discovery Today.</source><year>2021</year>, <volume>26</volume>, <fpage>80</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2020.10.010</pub-id>.<pub-id pub-id-type="pmid">33099022</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Gupta</surname><given-names>R.</given-names></name>; <name><surname>Srivastava</surname><given-names>D.</given-names></name>; <name><surname>Sahu</surname><given-names>M.</given-names></name>; <name><surname>Tiwari</surname><given-names>S.</given-names></name>; <name><surname>Ambasta</surname><given-names>R. K.</given-names></name>; <name><surname>Kumar</surname><given-names>P.</given-names></name><article-title>Artificial intelligence to deep learning:
Machine intelligence approach
for drug discovery</article-title>. <source>Mol. Divers.</source><year>2021</year>, <volume>25</volume>, <fpage>1315</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1007/s11030-021-10217-3</pub-id>.<pub-id pub-id-type="pmid">33844136</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Kwon</surname><given-names>S.</given-names></name>; <name><surname>Bae</surname><given-names>H.</given-names></name>; <name><surname>Jo</surname><given-names>J.</given-names></name>; <name><surname>Yoon</surname><given-names>S.</given-names></name><article-title>Comprehensive ensemble in QSAR prediction
for drug discovery</article-title>. <source>BMC Bioinform.</source><year>2019</year>, <volume>20</volume>, <fpage>521</fpage><pub-id pub-id-type="doi">10.1186/s12859-019-3135-4</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Neves</surname><given-names>B. J.</given-names></name>; <name><surname>Braga</surname><given-names>R. C.</given-names></name>; <name><surname>Melo-Filho</surname><given-names>C. C.</given-names></name>; <name><surname>Moreira-Filho</surname><given-names>J. T.</given-names></name>; <name><surname>Muratov</surname><given-names>E. N.</given-names></name>; <name><surname>Andrade</surname><given-names>C. H.</given-names></name><article-title>QSAR-Based Virtual
Screening: Advances
and Applications in Drug Discovery</article-title>. <source>Front. Pharm.</source><year>2018</year>, <volume>9</volume>, <fpage>1275</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01275</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Liu</surname><given-names>R.</given-names></name>; <name><surname>So</surname><given-names>S. S.</given-names></name><article-title>Development of quantitative
structure-property relationship models
for early ADME evaluation in drug discovery. 1. Aqueous solubility</article-title>. <source>J. Chem. Inf. Comput. Sci.</source><year>2001</year>, <volume>41</volume>, <fpage>1633</fpage>–<lpage>1639</lpage>. <pub-id pub-id-type="doi">10.1021/ci010289j</pub-id>.<pub-id pub-id-type="pmid">11749590</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Clark</surname><given-names>R. D.</given-names></name>; <name><surname>Daga</surname><given-names>P. R.</given-names></name><article-title>Building a Quantitative
Structure-Property Relationship
(QSPR) Model</article-title>. <source>Methods Mol. Biol.</source><year>2019</year>, <volume>1939</volume>, <fpage>139</fpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9089-4_8</pub-id>.<pub-id pub-id-type="pmid">30848460</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Sharp</surname><given-names>T.</given-names></name>; <name><surname>Barnes</surname><given-names>N. M.</given-names></name><article-title>Central 5-HT receptors
and their function; present
and future</article-title>. <source>Neuropharmacology.</source><year>2020</year>, <volume>177</volume>, <elocation-id>108155</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108155</pub-id>.<pub-id pub-id-type="pmid">32522572</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Rudnick</surname><given-names>G.</given-names></name>; <name><surname>Sandtner</surname><given-names>W.</given-names></name><article-title>Serotonin transport
in the 21st century</article-title>. <source>J. Gen Physiol.</source><year>2019</year>, <volume>151</volume> (<issue>11</issue>), <fpage>1248</fpage>–<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.201812066</pub-id>.<pub-id pub-id-type="pmid">31570504</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Newman-Tancredi</surname><given-names>A.</given-names></name>; <name><surname>Depoortère</surname><given-names>R. Y.</given-names></name>; <name><surname>Kleven</surname><given-names>M. S.</given-names></name>; <name><surname>Kołaczkowski</surname><given-names>M.</given-names></name>; <name><surname>Zimmer</surname><given-names>L.</given-names></name><article-title>Translating biased agonists from molecules to medications:
Serotonin 5-HT1A receptor functional selectivity for CNS disorders</article-title>. <source>Pharmacol Ther.</source><year>2022</year>, <volume>229</volume>, <elocation-id>107937</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107937</pub-id>.<pub-id pub-id-type="pmid">34174274</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Czub</surname><given-names>N.</given-names></name>; <name><surname>Szlęk</surname><given-names>J.</given-names></name>; <name><surname>Pacławski</surname><given-names>A.</given-names></name>; <name><surname>Klimończyk</surname><given-names>K.</given-names></name>; <name><surname>Puccetti</surname><given-names>M.</given-names></name>; <name><surname>Mendyk</surname><given-names>A.</given-names></name><article-title>Artificial
Intelligence-Based Quantitative
Structure-Property Relationship Model for Predicting Human Intestinal
Absorption of Compounds with Serotonergic Activity</article-title>. <source>Mol. Pharmaceutics</source><year>2023</year>, <volume>20</volume> (<issue>5</issue>), <fpage>2545</fpage>–<lpage>2555</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c01117</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="weblink" id="cit11">NovaDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dnastar.com/software/nova-protein-modeling/novadock/">https://www.dnastar.com/software/nova-protein-modeling/novadock/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="weblink" id="cit12">AutoDock. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://autodock.scripps.edu/">https://autodock.scripps.edu/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="weblink" id="cit13">VEGA
QSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/about-vegahub/">https://www.vegahub.eu/about-vegahub/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="weblink" id="cit14">QSAR
TOOLBOX. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://qsartoolbox.org/">https://qsartoolbox.org/</uri> (accessed October 23, 2023).</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Ambure</surname><given-names>P.</given-names></name>; <name><surname>Halder</surname><given-names>A. K.</given-names></name>; <name><surname>Gonzalez Diaz</surname><given-names>H.</given-names></name>; <name><surname>Cordeiro</surname><given-names>M. N. D. S.</given-names></name><article-title>QSAR-Co: An
Open Source Software for Developing Robust Multitasking or Multitarget
Classification-Based QSAR Models</article-title>. <source>J. Chem. Inf
Model.</source><year>2019</year>, <volume>59</volume> (<issue>6</issue>), <fpage>2538</fpage>–<lpage>2544</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b00295</pub-id>.<pub-id pub-id-type="pmid">31083984</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="weblink" id="cit16">PharmQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pharmacelera.com/pharmqsar/">https://pharmacelera.com/pharmqsar/</uri>, (accessed October 25, 2023).</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Guariento</surname><given-names>S.</given-names></name>; <name><surname>Franchini</surname><given-names>S.</given-names></name>; <name><surname>Tonelli</surname><given-names>M.</given-names></name>; et al. <article-title>Exhaustive CoMFA and
CoMSIA analyses around different chemical entities: a ligand-based
study exploring the affinity and selectivity profiles of 5-HT1A ligands</article-title>. <source>J. Enzyme Inhib Med. Chem.</source><year>2017</year>, <volume>32</volume> (<issue>1</issue>), <fpage>214</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1080/14756366.2016.1247057</pub-id>.<pub-id pub-id-type="pmid">28114832</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="weblink" id="cit18">AiQSAR. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vegahub.eu/portfolio-item/aiqsar/">https://www.vegahub.eu/portfolio-item/aiqsar/</uri> (accessed October 24, 2023).</mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Kausar</surname><given-names>S.</given-names></name>; <name><surname>Falcao</surname><given-names>A. O.</given-names></name><article-title>An automated framework for QSAR model building</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s13321-017-0256-5</pub-id>.<pub-id pub-id-type="pmid">29340790</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="weblink" id="cit20">The GNU
General Public License, Version 3, 29 June <year>2007</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gnu.org/licenses/gpl-3.0.html">https://www.gnu.org/licenses/gpl-3.0.html</uri> (accessed July 5, 2023).</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>ZINC—A free
database of commercially available
compounds for virtual screening</article-title>. <source>J. Chem. Inf.
Model.</source><year>2005</year>, <volume>45</volume>, <fpage>177</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id>.<pub-id pub-id-type="pmid">15667143</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>de Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M. P.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; et al. <article-title>ChEMBL: Towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume>, <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Cruz</surname><given-names>A.</given-names></name>; <name><surname>Ramsey</surname><given-names>S.</given-names></name>; et al. <article-title>Hidden bias in the DUD-E
dataset leads to misleading performance of deep learning in structure-based
virtual screening</article-title>. <source>PLoS One.</source><year>2019</year>, <volume>14</volume> (<issue>8</issue>), <elocation-id>e0220113</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0220113</pub-id>.<pub-id pub-id-type="pmid">31430292</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Miao</surname><given-names>R.</given-names></name>; <name><surname>Xia</surname><given-names>L. Y.</given-names></name>; <name><surname>Chen</surname><given-names>H. H.</given-names></name>; et al. <article-title>Improved Classification
of Blood-Brain-Barrier Drugs Using Deep Learning</article-title>. <source>Sci. Rep</source><year>2019</year>, <volume>9</volume>, <fpage>8802</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-44773-4</pub-id>.<pub-id pub-id-type="pmid">31217424</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="undeclared" id="cit25">Online chemical
database with modeling environment. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ochem.eu/home/show.do">https://ochem.eu/home/show.do</uri> (accessed July 16, 2023).</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Moriwaki</surname><given-names>H.</given-names></name>; <name><surname>Tian</surname><given-names>Y. S.</given-names></name>; <name><surname>Kawashita</surname><given-names>N.</given-names></name>; <name><surname>Takagi</surname><given-names>T.</given-names></name><article-title>Mordred: A molecular
descriptor calculator</article-title>. <source>J. Cheminform.</source><year>2018</year>, <volume>10</volume>, <fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0258-y</pub-id>.<pub-id pub-id-type="pmid">29411163</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="undeclared" id="cit27"><person-group person-group-type="allauthors"><name><surname>Plonska</surname><given-names>A.</given-names></name>; <name><surname>Plonski</surname><given-names>P.</given-names></name></person-group><article-title>MLJAR: State-of-the-Art
Automated Machine Learning Framework for Tabular Data</article-title>, version 0.10.3. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mljar/mljar-supervised">https://github.com/mljar/mljar-supervised</uri>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="weblink" id="cit28">Guidance
Document on the Validation of (Quantitative) Structure-Activity Relationship
[(Q)SAR] Models. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm">https://www.oecd.org/env/guidance-document-on-the-validation-of-quantitative-structure-activity-relationship-q-sar-models-9789264085442-en.htm</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Pälvimäki</surname><given-names>E. P.</given-names></name>; et al. <article-title>Interactions of selective serotonin reuptake inhibitors with the
serotonin 5-HT2C receptor</article-title>. <source>Psychopharmacology</source><year>1996</year>, <volume>126</volume>, <fpage>234</fpage>–<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1007/BF02246453</pub-id>.<pub-id pub-id-type="pmid">8876023</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Shapiro</surname><given-names>D. A.</given-names></name>; et al. <article-title>Aripiprazole, a novel
atypical antipsychotic drug with a unique and
robust pharmacology</article-title>. <source>Neuropsychopharmacology.</source><year>2003</year>, <volume>28</volume> (<issue>8</issue>), <fpage>1400</fpage>–<lpage>1411</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300203</pub-id>.<pub-id pub-id-type="pmid">12784105</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="weblink" id="cit31">Santa
Cruz. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scbt.com/p/zolmitriptan-139264-17-8">https://www.scbt.com/p/zolmitriptan-139264-17-8</uri> (accessed November
22, 2023).</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Cosi</surname><given-names>C.</given-names></name>; <name><surname>Koek</surname><given-names>W.</given-names></name><article-title>Agonist, antagonist,
and inverse agonist properties of antipsychotics
at human recombinant 5-HT<sub>1A</sub> receptors expressed in HeLa
cells</article-title>. <source>Eur. J. Pharmacol.</source><year>2001</year>, <volume>433</volume> (<issue>1</issue>), <fpage>55</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(01)01493-5</pub-id>.<pub-id pub-id-type="pmid">11755134</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Kaplan</surname><given-names>A. L.</given-names></name>; <name><surname>Confair</surname><given-names>D. N.</given-names></name>; <name><surname>Kim</surname><given-names>K.</given-names></name>; et al. <article-title>Bespoke library docking
for 5-HT2A receptor agonists with antidepressant activity</article-title>. <source>Nature.</source><year>2022</year>, <volume>610</volume>, <fpage>582</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05258-z</pub-id>.<pub-id pub-id-type="pmid">36171289</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Sparaco</surname><given-names>R.</given-names></name>; <name><surname>Kędzierska</surname><given-names>E.</given-names></name>; <name><surname>Kaczor</surname><given-names>A. A.</given-names></name>; <name><surname>Bielenica</surname><given-names>A.</given-names></name>; <name><surname>Magli</surname><given-names>E.</given-names></name>; <name><surname>Severino</surname><given-names>B.</given-names></name>; <name><surname>Corvino</surname><given-names>A.</given-names></name>; <name><surname>Gibuła-Tarłowska</surname><given-names>E.</given-names></name>; <name><surname>Kotlińska</surname><given-names>J. H.</given-names></name>; <name><surname>Andreozzi</surname><given-names>G.</given-names></name>; et al. <article-title>Synthesis, Docking Studies
and Pharmacological Evaluation of Serotoninergic Ligands Containing
a 5-Norbornene-2-Carboxamide Nucleus</article-title>. <source>Molecules.</source><year>2022</year>, <volume>27</volume> (<issue>19</issue>), <fpage>6492</fpage><pub-id pub-id-type="doi">10.3390/molecules27196492</pub-id>.<pub-id pub-id-type="pmid">36235029</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Levit
Kaplan</surname><given-names>A.</given-names></name>; <name><surname>Strachan</surname><given-names>R. T.</given-names></name>; <name><surname>Braz</surname><given-names>J. M.</given-names></name>; <name><surname>Craik</surname><given-names>V.</given-names></name>; <name><surname>Slocum</surname><given-names>S.</given-names></name>; <name><surname>Mangano</surname><given-names>T.</given-names></name>; <name><surname>Amabo</surname><given-names>V.</given-names></name>; <name><surname>O’Donnell</surname><given-names>H.</given-names></name>; <name><surname>Lak</surname><given-names>P.</given-names></name>; <name><surname>Basbaum</surname><given-names>A. I.</given-names></name>; <name><surname>Roth</surname><given-names>B. L.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name><article-title>Structure-Based
Design of a Chemical Probe Set for the 5-HT5A Serotonin Receptor</article-title>. <source>J. Med. Chem.</source><year>2022</year>, <volume>65</volume> (<issue>5</issue>), <fpage>4201</fpage>–<lpage>4217</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02031</pub-id>.<pub-id pub-id-type="pmid">35195401</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Łażewska</surname><given-names>D.</given-names></name>; <name><surname>Więcek</surname><given-names>M.</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>Chałupnik</surname><given-names>P.</given-names></name>; <name><surname>Żesławska</surname><given-names>E.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Tarasek</surname><given-names>M.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Szymańska</surname><given-names>E.</given-names></name>; et al. <article-title>New Triazine Derivatives as Serotonin
5-HT6 Receptor Ligands</article-title>. <source>Molecules.</source><year>2023</year>, <volume>28</volume> (<issue>3</issue>), <fpage>1108</fpage><pub-id pub-id-type="doi">10.3390/molecules28031108</pub-id>.<pub-id pub-id-type="pmid">36770774</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Czarnota-Łydka</surname><given-names>K.</given-names></name>; <name><surname>Sudoł-Tałaj</surname><given-names>S.</given-names></name>; <name><surname>Kucwaj-Brysz</surname><given-names>K.</given-names></name>; <name><surname>Kurczab</surname><given-names>R.ł</given-names></name>; <name><surname>Satała</surname><given-names>G.</given-names></name>; <name><surname>de Candia</surname><given-names>M.</given-names></name>; <name><surname>Samarelli</surname><given-names>F.</given-names></name>; <name><surname>Altomare</surname><given-names>C. D.</given-names></name>; <name><surname>Carocci</surname><given-names>A.</given-names></name>; <name><surname>Barbarossa</surname><given-names>A.</given-names></name>; <name><surname>Zesławska</surname><given-names>E.</given-names></name>; <name><surname>Głuch-Lutwin</surname><given-names>M.</given-names></name>; <name><surname>Mordyl</surname><given-names>B.</given-names></name>; <name><surname>Kubacka</surname><given-names>M.</given-names></name>; <name><surname>Wilczynska-Zawal</surname><given-names>N.</given-names></name>; <name><surname>Jastrzebska-Wiesek</surname><given-names>M.</given-names></name>; <name><surname>Partyka</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>N.</given-names></name>; <name><surname>Wiecek</surname><given-names>M.łg.</given-names></name>; <name><surname>Nitek</surname><given-names>W.</given-names></name>; <name><surname>Honkisz-Orzechowska</surname><given-names>E.</given-names></name>; <name><surname>Latacz</surname><given-names>G.</given-names></name>; <name><surname>Wesołowska</surname><given-names>A.</given-names></name>; <name><surname>Carrieri</surname><given-names>A.</given-names></name>; <name><surname>Handzlik</surname><given-names>J.</given-names></name><article-title>Synthesis,
computational and experimental pharmacological studies for (thio)ether-triazine
5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent
intrinsic activity in search for new class of drugs against Alzheimer’s
disease</article-title>. <source>Eur. J. Med. Chem.</source><year>2023</year>, <volume>259</volume>, <fpage>115695</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115695</pub-id>.<pub-id pub-id-type="pmid">37567058</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Penjisevic</surname><given-names>J. Z.</given-names></name>; <name><surname>Sukalovic</surname><given-names>V. B.</given-names></name>; <name><surname>Dukic-Stefanovic</surname><given-names>S.</given-names></name>; <name><surname>Deuther-Conrad</surname><given-names>W.</given-names></name>; <name><surname>Andric</surname><given-names>D. B.</given-names></name>; <name><surname>Kostic-Rajacic</surname><given-names>S.đa.
V.</given-names></name><article-title>Synthesis of novel 5-HT1A
arylpiperazine ligands: Binding data and computer-aided analysis of
pharmacological potency</article-title>. <source>Arab. J. Chem.</source><year>2023</year>, <volume>16</volume>, <fpage>104636</fpage><pub-id pub-id-type="doi">10.1016/j.arabjc.2023.104636</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="book" id="cit39"><person-group person-group-type="allauthors"><name><surname>Shapley</surname><given-names>L. S.</given-names></name></person-group><article-title>A Value for
N-Person Games</article-title>. <publisher-name>RAND Corporation</publisher-name>: <publisher-loc>Santa Monica, CA</publisher-loc>, <year>1952</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rand.org/pubs/papers/P295.html">https://www.rand.org/pubs/papers/P295.html</uri>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="undeclared" id="cit40"><person-group><name><surname>Lundberg</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>S. I.</given-names></name></person-group><article-title>A Unified Approach to Interpreting
Model Predictions</article-title>. <source>ArXiv Preprint</source>, arXiv:1705.07874, <year>2017</year>.</mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="undeclared" id="cit41"><person-group person-group-type="allauthors"><name><surname>Szlęk</surname><given-names>J.</given-names></name></person-group><article-title>Model
Interpretation</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/jszlek/MODEL_INTERPRETATION">https://github.com/jszlek/MODEL_INTERPRETATION</uri> (accessed July 15, 2023).</mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="weblink" id="cit42">Steamlit:
a faster way to build and share data apps. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://streamlit.io/">https://streamlit.io/</uri> (accessed
June 2, 2023).</mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Sivandzade</surname><given-names>F.</given-names></name>; <name><surname>Cucullo</surname><given-names>L.</given-names></name><article-title>In-vitro blood-brain
barrier modeling: A review of
modern and fast-advancing technologies</article-title>. <source>J. Cereb
Blood Flow Metab.</source><year>2018</year>, <volume>38</volume> (<issue>10</issue>), <fpage>1667</fpage>–<lpage>1681</lpage>. <pub-id pub-id-type="doi">10.1177/0271678X18788769</pub-id>.<pub-id pub-id-type="pmid">30058456</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="weblink" id="cit44">Canva. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canva.com/">https://www.canva.com/</uri> (accessed
10 June 2023).</mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="undeclared" id="cit45a">Streamlit
ketcher. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io">https://github.com/mik-laj/streamlit-ketcher?ref=blog.streamlit.io</uri> (accessed July 15, 2023).</mixed-citation>
      <mixed-citation publication-type="journal" id="cit45b"><name><surname>Abuhelwa</surname><given-names>A. Y.</given-names></name>; <name><surname>Williams</surname><given-names>D. B.</given-names></name>; <name><surname>Upton</surname><given-names>R. N.</given-names></name>; <name><surname>Foster</surname><given-names>D. J.</given-names></name><article-title>Food, gastrointestinal pH, and models of oral drug
absorption</article-title>. <source>Eur. J. Pharm. Biopharm.</source><year>2017</year>, <volume>112</volume>, <fpage>234</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2016.11.034</pub-id>.<pub-id pub-id-type="pmid">27914234</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
